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Glucocorticoids, a general introduction




Although the name glucocorticoids (GCs) refers to a class of steroid 
hormones produced by the adrenal cortex, the name is commonly 
used to indicate synthetic analogues of these molecules such as 
prednisolone. The endogenous glucocorticoid cortisol, is part of 
many different processes in the body, ranging from glucose 
metabolism to memory consolidation. And indeed cortisol also 
affects immunological processes such as regulation of delayed type 
hypersensitivity[1] or modulating the Th1/Th2 balance[2]. However, 
clinically GCs are used for the general suppression of inflammation. 
At supraphysiological concentrations, GCs can inhibit various aspects 
of both the innate and adaptive immune response[3]. Hence they 
are used for the treatment of allergies, auto-immune diseases and 
other inflammatory conditions. In general their effect is swift and 
powerful, unparalleled by other immunosuppressants. Combined 
with molecular properties that allow for different routes of 
administration, unhindered passage through the body and the low 
cost of production, make GCs a very attractive drug. Unfortunately, a 
proportion of patients becomes refractory to treatment and over 
time require an increasing dose[4]. Additionally, effects of treatment 
are not limited to suppression of inflammation alone but coincide 
with a wide range of adverse effects. The incidence of adverse 
effects increases along with the dose and prolonged exposure[5]. 
This can develop into serious complications, resulting in 
discontinuation of the treatment or worse. And so, taken together, 
GCs are both bitter and sweet. Considering the limited repertoire of 
anti-inflammatory drugs to our disposal, GCs cannot simply be 
disposed of. Smarter and improved versions of this drug need to be 
developed. But so far this has not proven to be an easy task[6]. Their 
potency may be explained by evolutionary development as an 
integral part of the human body. But this is also their weakness since 
the underlying mechanisms that regulate immunosuppression do not 




differ from those that cause adverse effects. Separating the two may 
not be possible and indeed, so far, no safe GC has been developed. It 
did, however, yield a myriad of information on how GCs work, 
changing insights and maybe one day, resulting in the development 
of a safe GC. 
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The field of glucocorticoids and the glucocorticoid receptor is quiet 
extensive. Currently (2015) a simple search on PubMed will return close to 
200.000 hits. This is related to the ever increasing interest but also for a 
part to the long history of glucocorticoid research which dates back to the 
eighteen hundreds. In 1855 Thomas Addison, a British physician, described 
a progressive destructive condition of the adrenal glands[1] which we now 
know renders patients glucocorticoid and mineralocorticoid deficient. 
Symptoms include low blood pressure, muscle weakness and low blood 
sugar. If left untreated patients may develop a severe condition termed 
Addisonian crisis which may be life-threatening. Nowadays patients 
suffering from adrenal insufficiency can be easily compensated by 
supplementing the lacking cortisol in the form of a tablet.  
Not long after Addison’s publication, a Mauritian physiologist named 
Charles-Edouard Brown-Sequard used animals to show that removal of the 
adrenal glands results in death which, as he correctly suggested, was due 
to a lack of hormones. It took another forty years before the next step was 
taken. In 1898 the Canadian physician Sir William Osler treated an 
Addisson’s patient with crude preparations of adrenal glands taken from 
animals, thereby temporarily improving symptoms of the disease[2]. His 
results strongly suggested that the adrenal glands produced a substance 
that was vital to the body. To establish this, both Hartman and Swingle 
adrenalectomized rats, cats and dogs, and prepared extracts with which 
the life of these animals could be maintained[3, 4]. These extracts have 
also been used effectively for the treatment of Addisons patients and at 
the time it was believed they contained a substance that could extend life 
in general. Therefore an international competitive search commenced 
which culminated in the discovery of cortisone in 1934. The American 
chemist Edward Kendall was the first to successfully isolate it. He 
discovered that the adrenal glands did not contain just one substance but 
that the effects caused by adrenalectomy are related to different groups of 
molecules, which he labeled alphabetically. Only four of these seemed to 
have a physiological effect in animals. 11-dehydrocorticosterone 
(compound A), corticosterone (compound B), dehydrocorticosterone 





hydroxycorticosterone (compound F)[5].  
Importantly, its use as an anti-inflammatory drug was completely 
unknown. Investigations were driven by a rumor during WWII that the 
Germans were performing large scale isolations from bovine adrenal glands 
in order to prevent hypoxia of Luftwaffe pilots enabling them to fly on 
higher altitudes. As a consequence it was in the interest of the war to 
quickly find a way to synthesize adrenal hormones. And although a use for 
these hormones in warfare could not be found, the first large scale 
synthesis of cortisone was completed by Kendall at the Mayo clinic (in 
collaboration with Lewis Sackett of Merck) in 1948.  
Dr. Philip S. Hench was Chief of the Medical Service and Director of the 
Army's Rheumatism Centre at the Army and Navy General Hospital during 
the war. When the war came to an end he specialized in arthritic disease at 
the Mayo clinic. There he noticed that particular conditions, such as 
pregnancy or jaundice, caused a remission of pain. From these 
observations he became convinced that this effect was caused by a steroid 
hormone. In 1949 Hench, in collaboration with Kendall, reported the 
successful treatment of rheumatoid arthritis patients with Compound E [6]. 
In 1950, for their work on hormones of the adrenal cortex, Hench, Kendall 
and Reichstein received the Nobel Prize in physiology or medicine. 
Interestingly to isolate 1 gram of cortisone, Kendall required 500 kilogram 
of adrenal glands, which he collected from 20.000 cows. It was not until 
1952 before a means of biological production was found, using the fungus 
Rhizopus nigricans.  
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As previously mentioned, the use of steroids is impeded by two major 
problems. The first problem is loss of response to treatment. In some 
patients response to treatment reduces over time, requiring a higher dose 
to maintain the initial response. But a proportion of this group grows 
entirely refractory to treatment. The underlying cause is unclear and still 
subject to debate[1]. The second objection to GC treatment is its 
associations with a rather large number of severe adverse effects, 
particularly when using a systemic high dose. These adverse effects have 
been studied quite extensively, with the intention of discovering ways to 
reduce or even prevent them. With some of these adverse effects the 
underlying GC driven mechanism has been fully elucidated. Here we will 
discuss in broad detail which adverse effects are associated with GC 
treatment and what is known about the underlying mechanism. 
GCs are synthetic analogues of a steroid hormone, which in the body 
serves a wide range of specific biological functions. Part of these functions 
is related to conditions such as stress or anxiety, which cause the levels of 
cortisol to increase[2]. In absence of stress, the level of cortisol fluctuates 
with a circadian rhythm, rising just before waking in the morning. This rise 
is believed to prepare people for the stress that is associated with everyday 
life[3].  
Secretion of cortisol is self-limiting because the hormone binds receptors in 
the hypothalamus and anterior pituitary gland, reducing secretion of CRH 
(corticotropin releasing hormone) and ACTH (adrenocorticotropic 
hormone) and thereby inhibiting the stimulus that causes production of 
cortisol. High levels of synthetic GCs have a similar effect but due to a 
higher affinity for the GR and longer half-life, the effect can be much 
stronger. As a result, production of cortisol can be inhibited for as long as 
two months after stopping the treatment. However, this problem can be 
quite easily solved by slowly decreasing the dosage before stopping 
treatment.   
Depending on the route of administration some adverse effects are more 





droplets) will have mainly local side effects. Here we will focus primarily on 
side effects associated with systemic administration. 
 Adipogenesis 
Next to the suppression of the hypothalamic-pituitary-adrenal function, 
long-term treatment with GCs can cause Cushing’s syndrome. This 
syndrome results from Cushing’s disease, a condition described by Harvey 
Cushing in 1932[4]. Overproduction of CRH or ACTH, for example due to an 
adenoma in the pituitary gland, results in elevated cortisol levels. Elevated 
levels have a profound effect on the human body and this effect is similar 
in patients who are treated with GCs. Striking is the change in appearance. 
Patients gain weight, particularly around the waist, back of neck (buffalo 
hump) and face (moonface). The cause for GC induced obesity is related to 
the biological role that GCs play in adipose tissue physiology. GCs can 
induce lipogenic genes (ACC, FAS) provided that insulin is present[5, 6], 
regulate lipolysis (ATGL, HSL, MGL)[7-9], adipose endocrine function 
(release of chemokines from the adipose tissue)[10] and restrain adipose 
tissue inflammation in obesity[11]. They are required for precursor cells to 
differentiate into adipocytes and necessary for keeping specific adipocyte 
related genes active to prevent isolated adipocytes or adipocyte tissue 
from dedifferentiation[12]. Interestingly, people suffering from obesity do 
not have increased blood cortisol levels but have higher local 
concentrations of cortisol in their adipose tissue. This is due to a higher 
activity of 11ß-hydroxysteroid dehydrogenase-1 (HSD1), which converts 
the inactive cortisone to cortisol[13]. In mice adipocyte specific 
overexpression of HSD1 leads to obesity with metabolic syndrome[14]. 
Apart from effects of GC treatment that relate to the adipose tissue, 
patients can experience an increased appetite[15]. The appetite in humans 
correlates with changes in adrenal steroid levels. Anorexia and weight loss 
for example is a typical symptom of Addison’s disease, caused by adrenal 
insufficiency. It may also provide an answer on why people feel the need to 
eat under stress related conditions as stress increases cortisol levels. But 





found to elicit both orexigenic and anorexigenic effects. GCs increase 
neuropeptides that increase the appetite (NPY and AgRP) but on the other 
hand also inhibits signals that are associated with anorexia such as CRH. 
Skin (thinning & striae) 
Another symptom of Cushing’s syndrome is the thinning of the skin and 
related to this, the appearance of striae. These symptoms are more 
common to topically applied steroids but also occur during systemic 
treatment. The skin adopts a paper like property, becoming fragile and 
easily damaged. Histological changes include a reduction of the 
epidermis[16], a decrease in keratinocyte size[17], reduction in the number 
of fibroblasts[18], rearrangement of the geometry of the dermal fibrous 
network[19], and a decrease in the size of both the cell layers and of the 
lipid lamellae that are in between the cell layers of the stratum 
corneum[20]. Because GCs reduce the production of collagen by 
fibroblasts[21], the skin becomes more rigid and less flexible. As a 
consequence the skin rips more easily resulting in stretch marks known as 
striae. These processes are affected in the skin because under normal 
conditions fibroblast proliferation, keratinocyte differentiation  and 
collagen production are regulated through the local production of cortisol 
by HSD1[22, 23]. In has been shown in mice that the adverse effects of GC 
treatment on the skin can be countered by selective inhibition of HSD1[24].  
Two of the most extensively studied adverse effects of GC treatment are 
loss of strength of bone and muscle[25]. The underlying mechanisms have 
been largely uncovered and may help prevent these side effects when GC 
treatment is compulsory.   
Muscle (loss of strength) 
Loss of muscle strength is a result of muscle atrophy. The breakdown of 
muscle is considered to be one of the major catabolic GC mechanisms[26]. 
GCs cause the thickness of the muscle fibers to reduce and the protein 
content of the myofibrils to decrease[27]. The decrease in protein content 





increased breakdown is the result of activation of the ubiquitin proteasome 
and lysosomal systems by increasing the expression of so called Atrogenes, 
genes that are involved in atrophy (FOXO, Atrogin-1, MuRF-1)[28]. The 
decreased protein synthesis results from a direct inhibition of the mTOR 
pathway by GCs[29]. The underlying cause of these changes in protein 
homeostasis may be the result of differences in expression of two growth 
factors which are produced in the muscle tissue; Insulin-like Growth Factor 
(IGF)-I[30], a muscle anabolic growth factor and Myostatin (Mstn)[31], a 
muscle catabolic growth factor. In animal models, muscle specific 
overexpression of IGF-I[32] or deletion of Mstn protect against GC induced 
muscle atrophy[33, 34]. GCs have been shown to inhibit IGF-I and to 
stimulate Mstn. The latter contains a GRE in the promoter region of the 
gene but more importantly, GCs stabilize Mstn mRNA[35]. 
Bone (loss of strength) 
 GCs can also greatly affect the health and quality of bones by suppression 
of osteoblast function and a reduction of bone mineral density[25]. But 
although high levels of GC can result in loss of bone, physiological 
concentrations of cortisol are important for the formation of bone mass. 
Tissue specific knockout of the GR in bone results in a reduction of the total 
bone mass[36]. And similarly, overexpression of HSD2 in osteoblasts 
reduces bone mass[37]. GC cause osteoblasts to produce Wnt proteins, 
which perform a paracrine function on neighboring mesenchymal stem 
cells[38]. The Wnt proteins induce Wnt signaling, which results in the 
accumulation of ß-catenin and the expression of transcription factor 
RUNX2 which together drive differentiation of stem cells into an 
osteoblastic lineage. Additionally, the Wnt proteins induce Mmp14 
production in chondrocytes[39]. This metalloproteinase is important for 
the breakdown of extracellular matrix during the process of ossification. 
Failure to do so causes developmental anomalies such as delayed 
intramembranous ossification of the cranium as is apparent from HSD2 





But despite, or maybe because, of the role GCs play in bone formation, 
patients receiving high levels of systemic GCs can expect to lose bone, up 
to 12% in the first year of treatment and 2-3% in the years thereafter[40]. 
High levels of GCs cause an inhibitory effect on the both the function and 
differentiation of osteoblasts and induce apoptosis in this cell type[41, 42]. 
As a result bone formation is inhibited in a matter of hours after starting 
GC treatment. In contrast to physiological concentrations, high levels of 
GCs inhibit production of Wnt proteins by mature osteoblasts[43]. 
Consequently mesenchymal stem cells do not accumulate ß-catenin or 
increase production of RUNX2[44]. Moreover, GCs increase expression of 
glycogen synthase kinase 3ß (GSK-3ß), a protein that drives ß-catenin 
ubiquitinylation and proteasomal degradation and increases the expression 
of proteins that inhibit Wnt signaling[45]. High levels of GCs also inhibit 
another important regulator of osteoblast differentiation, bone 
morphogenetic protein 2 (BMP2). Expression is inhibited directly but also 
by increasing the expression of follistatin and Dan, two BMP-2 antagonists 
[46] and decreasing expression of IL-11[47] which stimulates expression of 
BMP-2. The decrease in number of osteoblasts also decreases the amount 
of proteins produced by these cells such as collagen and osteocalcin. 
Although only shown in vitro, GCs arrest osteoblast cell cycle progression in 
the G0, G1 (amongst others by decreasing expression of Cyclin D2 and 
increasing expression of p27kip1) and G2 phase (by decreasing expression 
of Cyclin A)[48]. And finally, GCs induce apoptosis in osteoblasts by 
increasing the expression of pro-apoptotic genes (Bim, Bak, P53)[49] and 
decreasing the expression of pro-survival genes (Bcl-XL)[48].  
More than nighty percent of bone is made up of osteocytes. These cells are 
situated in oblong spaces called lacunae and are interconnected through 
small canals termed canaliculi. These canals serve as a way for cells to 
communicate, acquire nutrients and when necessary, the recruitment of 
osteoblasts. The fluid that is stored in this network of canals provides the 
bone with strength. Even in the case of minimal loss of bone, high levels of 
GCs reduce the number of osteoblasts which in turn causes fluid content 
and vascularity of the bone to decrease which leads to a reduction of bone 





autophagy[51]. Prolonged treatment causes a pathological buildup of 
autophagosomes in the osteocytes[52]. Material secreted from these 
autophagosomes pollutes the microenvironment of the osteocyte and 
results in cell death.  
Although GC treatment can also affect osteoclasts by extending their 
lifespan[53], the negative effect of GC treatment on bone quality relies 
mainly on osteoblasts and osteocytes. Protecting osteoclasts from GC 
treatment by cell specific overexpression of HSD2, had little effect on the 
quality of bone tissue[53]. This in contrast to the protection of osteoblasts 
(and osteocytes) from GCs in which case the quality of bones was 
maintained even in prolonged presence of high levels of GCs[41]. 
Glucose (diabetes) 
Much as the name suggests GCs play an important role in the metabolism 
and uptake of glucose[54]. GCs antagonize the effect of insulin and can 
have a profound effect on blood glucose levels. Prolonged elevated blood 
glucose levels (hyperglycemia) resulting from GCs is commonly referred to 
as steroid induced diabetes mellitus[55]. This type of diabetes is in most 
cases transient in nature and the situation will return to normal after the 
GC treatment is stopped.  
In response to high blood glucose levels, insulin is secreted by ß-cells in the 
pancreas. This causes the liver to increase conversion of glucose into 
glycogen through a process called glycogenesis. Insulin stimulates a Glut4 
transporter mediated uptake of glucose by adipocytes and skeletal muscle 
cells. The effects of GCs on blood glucose levels are exactly opposite[56] 
and cause the ß-cells to dysfunction[57]. Although not all the steps in ß-cell 
insulin release have been elucidated, it is clear that the uptake of glucose 
by ß-cells causes an increase in ATP-ADP ratio which closes ATP sensitive 
potassium channels resulting in depolarization of the cellular membrane, 
leading to an influx of calcium and ultimately exocytosis of insulin filled 
granules[58]. GCs decrease glucose metabolism in ß-cells and thereby 
impair insulin release, disabling the body to respond to high glucose levels. 





decreasing glucose uptake in response to insulin release. Moreover, GCs 
affect insulin receptor (IR) signaling by decreasing expression of direct 
downstream signaling molecules such as insulin receptor substrate 1 (IRS1), 
phosphoinositide 3-kinase (PI3k) and protein kinase B (PKB)[59]. In skeletal 
muscle cells this effect is aided by an increase in proteolysis[56].  The 
resulting increased amino acid concentration has been reported to 
interfere with insulin signaling. The decrease of signaling molecules 
downstream of the IR causes cells to be less sensitive to insulin, decreasing 
glucose uptake. In adipocytes it has been reported that GCs increase 
lipolysis through downregulation of cyclic-nucleotide phosphodiesterase 
3B[9]. An increase in lipolysis leads to elevated fatty acid plasma levels, 
which also negatively affects glucose uptake. And finally GCs have a direct 
effect on glycogen synthesis kinase 3 (GSK3) in skeletal muscle cells[60]. 
This leads to inactivation, causing a decrease in glucose conversion and 
thus blood glucose levels remain increased. 
Blood pressure (hypertension) 
Blood pressure is the cumulative result of blood volume, the viscosity of 
the blood and the resistance that is caused by vascular diameter and 
flexibility. This is regulated through the renin-angiotensin system and 
aldosterone release, which affects both vascular diameter and body fluid 
volume. Rise in blood pressure is a common side effect of GC treatment 
causing the cardiovascular associated mortality rate to increase 
fivefold[61]. In general it is assumed that the rise in blood pressure is the 
result of increased renal sodium and water reabsorption due to binding of 
GCs to the mineralocorticoid receptor (MR), also known as the aldosterone 
receptor[62]. Indeed GCs bind the MR just as easily as mineralocorticoids 
do. This off target effect of GC treatment will certainly play a role in GC 
induced hypertension. However, there are a number of observations that 
indicate that GCs induce hypertension primarily through activation of the 
GR. For example the glucocorticoid budesonide, commonly used for the 
treatment of asthma, can hardly bind the MR and yet, treatment induces 
hypertension[63]. More importantly, treatment with the GR antagonist 





syndrome even though (despite the close similarity with the GR) the MR 
shows no affinity for RU486[64, 65]. And finally, blocking sodium and water 
retention through treatment with the MR antagonist spironolactone does 
not prevent GC induced hypertension[66]. 
In light of the above, GC induced hypertension is unlikely to be the result of 
activation of the MR but appears to be regulated through the GR. Long-
term adjustment of blood pressure levels is regulated through the renin-
angiotensin system in the kidneys. The kidneys release renin from their 
afferent arterioles. Renin hydrolyzes circulating angiotensinogen into the 
peptide angiotensin I. This peptide is then converted in the lungs by 
angiotensin-converting enzyme (ACE) into the potent vasoconstrictor 
angiotensin II. The GR is expressed throughout the kidneys but its role in 
the kidneys is unclear. Several studies suggested a functional role for the 
GR in the kidneys, in some cases even a role that may affect blood pressure 
primarily through an increase in sodium reabsorption[67-70]. However, 
experiments in animals have repeatedly shown that GCs induce 
natriuresis[71], making these results difficult to interpret. And perhaps the 
conclusion should be that GCs affect blood pressure mainly through effects 
on vascular smooth muscle cells. This would also fit with the relatively 
short time it takes for GC treatment to increase blood pressure. One study 
revealed that phenylephrine-induced vasoconstriction of isolated aortic 
rings is enhanced in a dose dependent manner by GC treatment[72]. This 
effect was blocked by pretreatment with L-NAME, an endothelial specific 
inhibitor of cGMP, suggesting that the effect might be dependent on 
endothelial cells. Indeed, in a recent study where the GR was conditionally 
knocked out in either smooth muscle cells or vascular endothelium, the 
latter appeared completely resistant to GC induced hypertension 
supporting a role for vascular endothelium[73]. And finally in vivo data 
obtained from a hypertension model in rats revealed that the effect of GCs 
on total peripheral pressure could be rescued by concomitant treatment 
with the vasodilator minoxidil, even though the GC induced hypertension 
remained unchanged[74]. This was explained by an increase in cardiac 





many systems and cell types involved, further research is required to fully 
clarify this adverse effect.  
Eye 
Over time GC treatment increases the risk of developing glaucoma or 
cataract dose dependently [75]. Cataract is a clouding of the lens, which 
decreases vision. Although development of cataract as an adverse effect of 
GC treatment normally takes months or even years to develop, cases have 
been reported in which patients on a low dose developed cataract after 
only two months[76]. GCs induce a specific type of cataract, which is 
located in the center (pole) at back of the lens, termed posterior 
subcapsular cataract (PSC). This cataract is characterized by aberrant lens 
epithelial cells that have migrated from the lens equator to the pole. 
Although it has been challenged for a long time, recent studies have 
revealed the presence of a functional GR in these cells[77]. Treatment with 
GCs induces transcription of a number of genes of which GILZ and PAI-1[78] 
are most prominent. Although no functional data is available, both are 
involved in apoptosis, differentiation and migration. In GC induced cataract 
the proliferation and differentiation of lens epithelial cells is confounded. 
Normally the lens is replenished by new lens fibers through the 
differentiation of epithelial cells on the lens equator, into fiber cells lacking 
DNA and organelles. In PSC histological studies revealed the presence of 
semi-differentiated cells containing degenerating nuclei and few organelles 
on the posterior pole of the lens[79]. Another important mechanism in the 
etiology of PSC seems to be the reduction of lens glutathione (GSH)[80]. 
This molecule is the body’s most potent antioxidant and protects 
macromolecules against reactive oxygen species and helps with H2O2 
detoxification. Reduction of GSH is considered to be the main mechanism 
behind age related cataract and its role in PSC is similar. Experiments with 
in vitro cultured lenses showed that the effect of GC on GSH could be 
rescued with RU486[81], demonstrating involvement of the GR. The last 
and longest existing hypothesis on GC induced PSC is based on an 
interaction between steroids and lens proteins which eventually leads to 





are often contradictory but its role cannot be denied and probably plays a 
part in PSC. 
A second adverse effect of GC treatment that affects the eye is GC induced 
glaucoma[83]. Glaucoma is an increase of intraocular pressure that may 
result in optic neuropathy if left untreated for too long. Changes in 
intraocular pressure are normal and pressure reflects the diurnal cortisol 
levels in the blood[84]. Adrenalectomized patients lack these diurnal 
changes in pressure supporting a role for cortisol in intraocular pressure. 
The pressure increases due to a decreased outflow of the aqueous 
humour[85], the fluid in the anterior chamber. It is believed that GCs 
increase outflow resistance by inhibiting degradation of extracellular 
matrix material in the trabecular meshwork[86]. This is the tissue that 
separates the anterior chamber from Schlemm’s canal, the canal that 
serves to deliver the humour to the bloodstream. There is substantial 
evidence that supports the deposition of extracellular matrix[87-91] but 
the underlying mechanism remains to be elucidated.  
The central nervous system 
GCs play an important role in the central nervous system (CNS) both in 
function and in homeostasis. The elevated levels that result from GC 
treatment or Cushing’s syndrome can have profound effects on the 
anatomy of the brain and increase the risk of developing psychiatric 
diseases, cognitive impairment, mood changes and sleep disturbances[92]. 
GCs can pass the blood brain barrier and exert their effect anywhere in the 
brain. This includes binding the GR in cerebral neurons and glial cells but 
also binding of MR in the limbic system[93]. Effects of GCs on the nervous 
system include non-genomic effects such as the rapid (>2 min) changes in 
electrical activity of neurons[94]. Long term exposure affects regenerative 
sprouting of axons that follows differentiation of hippocampal neurons[95], 
one of the two places in the CNS that is allowed to regenerate. It may lead 






These effects on the CNS may have serious implications. The hippocampus 
is pivotal for processing and the storage of memories[97]. A striking 
example is why some distinct memories are long lasting and in great detail 
while most other memories are only vaguely remembered for a short time. 
The cause lies in the elevation of cortisol levels during moments of arousal, 
stress or excitement. This mechanism of memory consolidation is very 
likely evolved as means to ensure survival, retaining information more 
easily during moments of stress or trauma[98]. However, chronic stress or 
chronically elevated cortisol levels in Addison's disease or during 
treatment, can induce amnesia[99] but also cause problems with visual-
spatial processing, conditional response, reasoning and verbal 
fluency[100]. This is also reflected in Cushing patients who learn at a slower 
pace, have a smaller short-term memory volume, memory contamination 
and false appraisal of task performance[101] suggesting extrahippocampal 
effects of glucocorticoids on memory impairment such as the amygdala 
and prefrontal cortex. Both are involved in connecting emotions to 
experience. 
When considering the use of GCs, adverse effects on behavior or emotional 
state are rarely contemplated. And yet 75% of patients treated with GCs 
experience mood disturbance, which in 5% is quiet severe[102]. These 
effects have been described since GCs entered the clinic in the early fifties. 
And unlike osteoporosis, muscle atrophy or the thinning of skin, adverse 
effects on the CNS can take as little as one dose. Adverse effects on the 
CNS include a wide range of cognitive and emotional effects, including 
agitation, anxiety, apathy, auditory and visual hallucinations, delusions, 
depression, distractibility, disturbances of body image, emotional lability, 
hypomania, insomnia, intermittent memory impairment, mutism, 
perplexity, pressured speech, and sensory flooding[103]. In rare cases 
patients can develop serious psychotic disorders or even delirium[104] and 
dementia[105]. But even if there is no doubt that these adverse effects are 
associated with the use of GCs, it is difficult to predict which patients are at 
risk. Certainly patients with a predisposition to a certain effect are more 
susceptible. Often the effects are limited, because the treatment is short, 






The list of adverse events that accompany GC treatment is long. Some are 
rare and have not been studied in great detail. Often the effects are 
reversible and the inconvenience for the patient very limited. However 
there are a few adverse effects that were not discussed here that can have 
major implications for the patient.  
GC treatment is associated with an increased risk of cardiovascular 
diseases[106]. In particular ischemic heart disease, heart failure and 
atherosclerosis. The latter is believed to be the result of increased lipid 
levels in the blood but studies yielded contradictory results. 
GCs increase the chance of adverse events in the gastrointestinal tract[107] 
including gastritis, ulcer formation, and gastrointestinal bleeding. The 
increase risk is small and causes most likely relate to suppression of the 
immune system. GCs also increase the risk of pancreatitis. Underlying 
cause is unclear.  
And finally the chance of infection should be taken in account[108]. GCs 
are excellent anti-inflammatory drugs that reduce the ability of both the 
innate- and the adaptive- immune system to deal with invading pathogens. 
Common bacteria that under normal conditions pose no threat can 
become a real issue. Normal signs of infection can be absent due to 
suppression of inflammatory mediators such as cytokines. 
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Glucocorticoid analogue development; 
things to consider…




Considering the numerous side effects and loss of response, todays GC 
analogues are far from ideal. They are very powerful immunosuppressants 
and indeed, when it comes down to the treatment of inflammation it may 
be difficult to discover a more effective alternative. But loss of response 
and adverse effects are serious problems that can limit clinical application. 
With a worldwide rise in the incidence of allergies[1] and autoimmune 
diseases[2], the need for powerful immunosuppressant’s with a favorable 
safety profile will only intensify. The chance of finding a more potent 
immunosuppressant seems very slim as GCs are an integral part of human 
design. So perhaps the most successful approach remains design of an 
alternative GC. And indeed, the current list of synthetic GC analogues is 
long. The search for GCs with a more favorable safety profile is a 
continuous search that started decades ago[3]. Although this has not led to 
the discovery of an ideal immunosuppressant it did improve GCs for 
specific conditions such as eczema or asthma. But more importantly, it 
provided a treasure of information on GC action. 
Glucocorticoids are small lipophilic molecules that can pass the cellular 
membrane unhindered. In general GCs act through binding to their cognate 
receptor, the glucocorticoid receptor (GR). This receptor is expressed by 
virtually all tissue types, where it resides in the cytoplasm when not bound 
to a ligand. In this resting state the GR is associated with a complex of 
chaperone proteins, which stabilize the GR in a conformation that allows 
binding of ligand. Classic GC action involves binding to the GR followed by 
dissociation of that GR from its chaperone complex exposing nuclear 
localization sequences. This causes the GR to be shuttled into the nucleus 
where, similar to other nuclear hormone receptors, it acts as a ligand 
activated transcription factor. Binding of an agonistic ligand causes the 
receptor to dimerize and translocate to the nucleus where it regulates 
particular genes but the GR has also been reported to enter the nucleus as 
a monomer. Which action follows binding of a ligand is dependent on many 
factors, such as the type of ligand it binds and the proteins it associates 
with. The latter is dependent on the tissue it is expressed in and the state 





predispose for a particular ligand and that binding of a certain ligand favors 
particular associations[4, 5]. 
Similar to other receptors of the nuclear hormone family, the 
glucocorticoid receptor consists of three domains[6]. From beginning to 
end the receptor consist of an N-terminal domain, a central DNA binding 
domain (DBD), and a C-terminal ligand binding domain (LBD). The N-
terminal domain contains activation function 1 (AF-1), an unstructured 
region that can interact with transcription factors such as AF-1 or TATA box 
binding protein (TBP)[7, 8]. It is not entirely clear if binding of transcription 
factors define the conformation of this region or whether the conformation 
of this region determines the transcription factors that can bind to it. The 
DBD is the part of the receptor responsible for the interaction with DNA. 
Two zinc-finger domains in the DBD allow for direct binding to palindromic 
glucocorticoid responsive elements present in promoter regions of 
genes[9]. And finally the LBD is the part of the receptor that can bind 
ligand. It too contains a motif for transcriptional activation termed AF-2. 
But unlike AF-1 this region is more organized, into a structure which is 
commonly referred to as the binding pocket. Apart from ligand, it can also 
associate with chaperones and coactivators[10, 11].  
The best described and most extensively studied mechanism of GC action is 
direct binding of GR homodimers to structures in the DNA known as 
glucocorticoid responsive elements (GRE). These elements consist of a 
particular set of nucleotides (TGTTCTnnnAGAACA) forming palindromic 
structures within the promoter region of genes[12]. Both parts of the 
homodimer bind on each side of the palindrome. This interaction 
stimulates transcription of target genes and is commonly referred to as 
transactivation. Many adverse effects associated with GC treatment are 
attributed to transactivation[13]. Suppression of the immune response, on 
the other hand, is in general the result of inhibition of transcription of pro-
inflammatory genes, termed transrepression. Initially it was believed that 
this process was regulated through negative GREs able to inhibit 
transcription through direct binding of the GR to DNA, for example by 
blocking binding of transcription factors[14]. And although this has been 




shown for some genes, in most cases transrepression relies on a process of 
tethering. The GR interacts with transcription factors directly and 
influences their activity[15]. 
The dichotomy in GR action has given the impression that the possibility 
exists of creating a GR ligand that discriminates between induction and 
repression of genes. Such a selective glucocorticoid receptor agonists 
(SEGRA) would have the benefit of providing immune suppression without 
adverse effects[16]. This idea stems from the development of the GRdim 
mouse. This mouse strain expresses a GR variant that contains a mutation 
in the dimerization domain disabling formation of homodimers, 
theoretically blocking transactivation[17]. Unlike mice in which the GR is 
knocked out, GRdim are viable, suggesting that transactivation is an 
expendable part of GR action and that other effects, such as 
transrepression, are more important. In the wake of this finding, many set 
out to develop SEGRAs but more than 20 years of research and 
development did not provide a true SEGRA. Nevertheless, SEGRAs for 
treatment of specific conditions such as rheumatoid arthritis[18] or atopic 
dermatitis[19] have been developed. Although these are not completely 
free from adverse effects they do provide an improved alternative.  
In recent years it has become increasingly clear that GC action cannot be 
divided in good and bad by separating in transactivation and 
transrepression. First off, transactivation does not always lead to adverse 
effects. For example GC activate the anti-inflammatory genes IκBα[20], 
GILZ[21] and Annexin-A1[22], which are all considered to have an anti-
inflammatory effect. Secondly, transactivation does not always require the 
GR to homodimerize. In one report it was demonstrated that mutations in 
the dimerization domain of the GR actually increased expression of the 
phenylethanolamine N-methyltransferase (PNMT) gene[23]. The promoter 
sequence of this gene doesn’t contain a normal palindromic GRE but 
interspaced half GREs. Mutation of one of these half GREs has little effect 
on promoter activity but when mutations are inserted in two or more, the 
activity is dramatically decreased. It is assumed that the GR forms 





form heterodimers with other related nuclear hormone receptors such as 
the androgen receptor or mineralocorticoid receptor resulting in a complex 
that is able to regulate genes in a fashion distinct from GR 
homodimers[24]. Formation of these dimers is not dependent on the GR 
dimerization domain as they can form even when the dimerization domain 
is mutated.  
Gene regulation is an important and powerful way for GC to affect cells. 
But this is not the only way in which GCs can act. With high concentrations, 
GCs can cause rapid effects that do not require regulation of genes, so-
called non-genomic or non-transcriptional GC effects[25]. For example 
dexamethasone causes an acute rise in eNOS production, an effect that 
does not require the receptor to enter the nucleus and is dependent on the 
PI3/Akt pathway[26]. But not all non-genomic effects include the GR and 
sometimes a distinction is made between specific non-genomic GC effects 
and non-specific non-genomic GC effects[27]. An example is the fast 
depolarization of neurons upon GC administration, which is considered to 
be an effect of GCs on the cellular membrane[28]. 
The glucocorticoid receptor is not a rigid molecule. It changes 
conformation upon binding to a ligand or when it associates with another 
molecule[29]. A very clear example is exposure of the nuclear translocation 
signal. A ligand binding the GR causes a conformational change uncovering 
motives on the GR that function as nuclear translocation signals. As a result 
the GR is shuttled into the nucleus[30]. Likewise, binding of ligand 
facilitates association with co-activators (TIF2[31], NCoR[32], SCR-1[33]), 
molecules that are characterized by socalled LXXLL motives[34], able to 
interact with the ligand binding domain of the GR. Association with co-
activators affects regulation of genes by the GR. TIF2 is known to acylate 
histones, making DNA more accessible to the GR whereas NCoR recruits 
histone deacetylases causing the DNA to be more condense and thus 
making DNA less accessible to the GR. Which coactivator can bind is 
dependent on how the ligand shapes the GR ligand binding pocket. 




But it is not only binding of ligands that affect the GR conformation. 
Association with proteins can affect the conformation as well. The best 
described mechanism is the interaction with the chaperone protein Hsp90 
which causes the GR to take on a shape that increases its ligand binding 
affinity[35].  
It is very likely that every interaction of the GR with other molecules will 
affect its conformation. The resulting change may alter its function, spatial 
distribution within the cell or limit the molecular partners it can interact 
with or even the ligands it can bind. In a ligand free environment the 
conformation would be determined primarily by the associated proteins, a 
factor that is dependent on the cell type the GR is expressed in. Often the 
GR is part of a multi protein complex, which can contain kinases (Src[36]) or 
even receptors (RXRB[37], TCR[38]). However, most of the proteins 
associated with the GR that have been identified so far are co-activators 
(NCOA1-4)[39], proteins that interact with transcription factors (BAG1[40], 
CREBBP[41]) or transcription factors (STAT3[42], STAT5[43]), all of which 
associate after activation of the receptor. These interactions determine 
which genes are regulated by allowing interaction with specific 
transcription factor, blocking access to DNA by direct interaction with GREs 
or allowing easier access to certain genes by relaxing the chromatin 
structure. In a similar fashion these interactions affect the amount of 
transcript that is produced. 
The complexity of GC action makes it very difficult to develop a screening 
assay that will allow for discovery of an overall better GC. On the one hand 
it will have to account for the different ways in which GCs affect a cell 
(genomic and non-genomic) and on the other hand it will have to correct 
for the type of cell and possibly even the condition that cell is in (GC action 
varies depending on the environment). Obviously a screening assay that 
simply focuses on high affinity for the GR will improve the anti-
inflammatory effect but increase adverse effects equally. Screening in a 
cancer cell line will provide results that will probably only translate back to 
that particular cell line. Using animals as a screening tool, apart from 





translate to the human situation. So perhaps, with the current 
understandings, the best approach for developing better GC analogues 
would be to focus on a particular condition or a specific set of target cells.  
The strategy presented in this thesis is based on the hypothesis that most 
effects of GC treatment are the result of GR mediated transcriptional 
regulation. This includes both the anti-inflammatory effects and the 
adverse effects. However, we found that GC mediated T cell inhibition is, at 
least in part, regulated through a non-genomic effect. We therefore 
decided to use this as a model, focusing on non-genomic inhibition of T cell 
proliferation while at the same time screening for transactivation with the 
goal to develop a GC analogue that inhibits T cell proliferation non-
genomically without resulting in GC induced transactivation. This is in 
theory a sound strategy because most of the adverse effects are indeed the 
result of GR mediated transcriptional regulation. However, future research 
may reveal many more non-genomic effects of GC treatment, including 
effects that are related to adverse effects. Currently such effects have only 
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Although glucocorticoid (GC)-induced nongenomic effects have been 
reported, the underlying mechanisms remain unexplained. We previously 
described that lymphocyte-specific protein tyrosine kinase (LCK) and FYN 
oncogene related to SRC, FGR, YES (FYN) mediate GC-induced inhibition of 
T-cell-receptor (TCR) signalling. Here we characterize the underlying 
molecular mechanism. The present study shows that the GC receptor is 
part of a TCR-linked multiprotein complex containing heat-shock protein 
(HSP)90, LCK and FYN, which is essential for TCR-dependent LCK/FYN 
activation. Experiments with cells transfected with GC-receptor short 
interfering RNA (siRNA) showed that the GC receptor is an essential 
component of the TCR signalling complex. Short-term GC treatment 
induces dissociation of this protein complex, resulting in impaired TCR 
signalling as a consequence of abrogated LCK/FYN activation. HSP90siRNA-
transfected cells are not able to assemble this TCR-associated multiprotein 
complex, and accordingly HSP90siRNA treatment mimics GC effects on 
LCK/FYN activities. These observations support a model for nongenomic 
GC-induced immunosuppression on the basis of dissolution of membrane-






Glucocorticoids (GCs) mediate their immunosuppressive effects through 
cytosolic ligand-inducible receptors (Buttgereit et al, 2004). Inactive GC 
receptors (GRs) are associated with (co)chaperones, such as heat-shock 
protein 90 (HSP90), which dissociate after GR ligation, followed by nuclear 
translocation of GR and regulation of gene transcription (Franchimont, 
2004; Pratt et al, 2004). GCs also evoke nongenomic effects on cellular 
function, which occur in minutes (Baus et al, 1996; Croxtall et al, 2000; 
Rhen & Cidlowski, 2005). Cardiovascular protective effects of GCs that 
could not be mediated by genomic mechanisms have been reported, 
because they occurred too fast and could not be blocked by a transcription 
inhibitor (Hafezi-Moghadam et al, 2002). Recently, we generated a 
comprehensive profile of such GC-induced rapid effects on signal 
transduction using activated human CD4+ T lymphocytes and a peptide 
array for kinome analysis (Lowenberg et al, 2005). The results showed 
marked early effects of GC treatment, in particular suppressed 
phosphorylation of LCK/FYN kinase consensus substrates. Further studies 
showed impaired recruitment of LCK and FYN to the T-cell-receptor (TCR) 
complex, resulting in reduced LCK/FYN enzymatic activities and impaired 
TCR signalling after short-term GC treatment. Although these studies 
identified LCK and FYN as cellular targets for nongenomic GC activities, the 
underlying mechanism remains unexplained. 
LCK and FYN are members of the SRC family of non-receptor tyrosine 
kinases and have a key role in TCR signalling. TCR activation results in 
membrane translocation of LCK and FYN in an HSP90-dependent manner 
(Bijlmakers & Marsh, 2000; Zamoyska et al, 2003; Palacios & Weiss, 2004). 
LCK predominantly associates with CD4 or CD8 cell-surface receptors and 
FYN binds to CD3 co-receptors, resulting in LCK and FYN kinase activation. 
Once activated, LCK and FYN phosphorylate immunoreceptor tyrosine-
based activation motifs (ITAMs) on the TCR, allowing downstream signal 
transduction and eventually T-cell cytokine production, proliferation and 
differentiation. GRs and SRC-like kinases share a requirement for HSP90 for 
proper functioning, opening the possibility that GR action on LCK and FYN 




activities is mediated by HSP90. The present study shows that GCs cause 
disruption of TCR-associated multiprotein complexes containing GR, HSP90, 
LCK and FYN, leading to reduced LCK/FYN enzymatic activities and impaired 
TCR signalling. 
Results 
DEX inhibits GR–HSP90–LCK/FYN interactions 
We examined the action of short-term treatment with the synthetic 
fluorinated GC dexamethasone (DEX) on the physical interactions of 
HSP90–LCK and HSP90–FYN. Cell lysates were subjected to LCK and FYN 
immunoprecipitation and analysed on western blot for the presence of 
HSP90. These experiments showed HSP90–LCK and HSP90–FYN 
interactions (Fig 1A), confirming previous studies (Hartson et al, 1996; 
Bijlmakers & Marsh, 2000; Yun & Matts, 2005). DEX treatment (30 min) 
resulted in the disappearance of these HSP90–LCK and HSP90–FYN 
complexes, suggesting that DEX rapidly inhibits HSP90–LCK and HSP90–FYN 
associations. Next, we investigated whether these DEX-sensitive HSP90–
LCK and HSP90–FYN complexes contained GR. Cells were pretreated for 10 
min with DEX or dimethyl sulphoxide (DMSO), followed by 15 min 
activation using CD3 and CD28 antibodies. LCK and FYN 
immunoprecipitates were immunoblotted for the presence of GR, showing 
GR–LCK and GR–FYN complexes in activated cells, and these associations 
disappeared after short-term DEX treatment (Fig 1B). These observations 
indicate that LCK, FYN, HSP90 and GR are part of a multiprotein complex 







Figure 1.  
Dexamethasone rapidly inhibits GR–HSP90–LCK and GR–HSP90–FYN 
associations. (A) Cells were incubated for 10 or 30 min with DEX (1 μM) or 
solvent‐supplemented media (−). LCK and FYN immunoprecipitates were 
analysed on western blot for the presence of HSP90, and total LCK/FYN 
levels were analysed to test for equal protein loading. (B) HSP90siRNA-
transfected or nontransfected cells were pretreated for 10 min without (−) 
or with (+) DEX and activated for 15 min with CD3 and CD28 antibodies. 
Lysates were subjected to LCK and FYN immunoprecipitation followed by 
western blotting for the presence of GR or HSP90. Equal loading was 
verified using LCK and FYN antibodies. Supernatants were subjected to 
immunoprecipitation using MEK antibody, followed by immunoblotting for 
MEK and b-Raf (negative immunoprecipitation control). Three independent 





experiments were performed and reproducible results were obtained. DEX, 
dexamethasone; FYN, FYN oncogene related to SRC, FGR, YES; GR, 
glucocorticoid receptor; HSP90, heat-shock protein 90; IB, immunoblotting; 
IP, immunoprecipitation; LCK, lymphocyte-specific protein tyrosine kinase; 
MEK, mitogen-activated protein kinase kinase. 
GR and HSP90-dependent LCK–CD4 or FYN–CD3 binding 
HSP90-dependent cellular distribution of LCK and FYN is essential for 
efficient TCR signalling. To determine the role of HSP90 in LCK–CD4 and 
FYN–CD3 associations, cells were transfected with HSP90 short interfering 
RNA (HSP90siRNA), followed by 10 min DEX pretreatment and 15 min 
activation. LCK–CD4 and FYN–CD3 interactions were detected in CD4 and 
CD3 immunoprecipitates prepared from activated cells (Fig 2A). These 
interactions were disrupted on treatment with HSP90siRNA, irrespective of 
DEX stimulation. Furthermore, GR–CD4 and GR–CD3 associations were 
seen in activated cells, and treatment with DEX or HSP90siRNA resulted in 
reduced GR–CD4 and GR–CD3 binding (Fig 2A). Cell lysates were subjected 
to GR immunoprecipitation, confirming DEX- and HSP90-sensitive GR–LCK 
and GR–CD4 interactions (supplementary Fig 1 online). In addition, cells 
were pretreated with the HSP90 inhibitor geldanamycin for 30 min, 
followed by 10 min DEX treatment and 15 min stimulation. LCK and FYN 
immunoprecipitates were immunoblotted for the presence of GR, 
confirming reduced LCK–GR and FYN–GR bindings owing to HSP90 
inhibition (Fig 2B). These observations indicate that TCR-associated 
multiprotein complexes are formed in activated cells (containing GR, 
HSP90, LCK and FYN), which depend on the presence of HSP90, and are 
disrupted on short-term DEX incubation. Complex dissolution does not lead 
to LCK or FYN degradation, as total LCK/FYN protein levels were not 
affected by HSP90siRNA or DEX (data not shown). Given that HSP90 
associates readily with unfolded proteins (such as ZAP70) and can 
therefore be nonspecifically immunoprecipitated, we studied whether DEX 
interferes with ZAP70–HSP90 bindings. These data indicated that the 
observed effects of DEX are specific for SRC-family kinases, as DEX did not 






online). These results were supported by the lack of effect of either DEX or 
HSP90siRNA on the integrity and functional activity of b-Raf/mitogen-
activated protein kinase kinase protein complexes (supplementary Fig 3 
online). Hence, DEX treatment does not interfere with protein complex 
formation per se, but specifically targets LCK–HSP90 and FYN–HSP90 
formations. The transfection procedure was evaluated by immunoblotting 
cellular extracts prepared from cells transfected with or without 
HSP90siRNA (supplementary Fig 4 online). To investigate further whether 
the presence of GR is required for efficient TCR signalling, GRsiRNA-
transfected cells were pretreated for 10 min with DEX followed by 15 min 
stimulation. Western blotting showed impaired TCR signalling in GRsiRNA-
transfected cells, as indicated by suppressed phosphorylation of several 
downstream TCR signalling intermediates (Fig 2C). These findings provide 
direct evidence that the GR is important in mediating efficient TCR 
signalling. As GRsiRNA might induce nonspecific effects, cells were 
transfected with control siRNA, demonstrating that the observed effects on 
TCR signalling are not a result of nonspecific GRsiRNA action 
(supplementary Fig 5 online). 






Figure 2.  
GR and HSP90-dependent LCK–CD4 and FYN–CD3 formations. (A) 






for 10 min in the presence (+) or absence (−) of DEX (1 μM) and incubated 
with (+) or without (−) CD3/CD28 antibodies for 15 min. CD3 and CD4 
immunoprecipitates were immunoblotted using the indicated antibodies. 
To ensure specificity in these experiments, the presence of FYN and LCK 
was analysed in CD4 and CD3 immunoprecipitates, respectively, 
demonstrating that specific complexes had been immunoprecipitated 
containing either FYN and CD3 or LCK and CD4. (B) Cells were pretreated 
for 30 min with geldanamycin (5 μM), followed by 10 min DEX treatment 
and 15 min activation (CD3/CD28 antibodies). LCK/FYN immunoprecipitates 
were immunoblotted for the presence of GR, and LCK and FYN antibodies 
were used to evaluate for equal loading. An irrelevant protein (that is, 
MEK) was immunoprecipitated from these lysates followed by western 
blotting using MEK antibody (immunoprecipitation controls). (C) GRsiRNA-
transfected or nontransfected cells were pretreated with DEX (10 min), 
followed by 15 min activation. Lysates were immunoblotted using 
phosphospecific antibodies against TCR signalling intermediates, and 
appropriate antibodies were used to test for equal loading. (D) Cell lysates, 
treated as described above, were subjected to LCK/FYN 
immunoprecipitation followed by in vitro kinase assays using SAM68 as a 
substrate. Phosphorylated SAM68 was immunoblotted with PY20, and 
equal loading was verified using LCK and FYN antibodies. Experiments were 
performed three times and representative results are shown. DEX, 
dexamethasone; ERK, extracellular-signal-regulated kinase; FYN, FYN 
oncogene related to SRC, FGR, YES; GR, glucocorticoid receptor; IB, 
immunoblotting; IP, immunoprecipitation; JNK, Jun amino-terminal kinase; 
LCK, lymphocyte-specific protein tyrosine kinase; MEK, mitogen-activated 
protein kinase kinase; P, phosphorylated; SAM68, SRC-associated in 
mitosis. 
HSP90siRNA inhibits LCK and FYN activities 
To investigate the functional consequences of dissolution of these 
multiprotein complexes on TCR-induced activation of LCK and FYN, we 
examined whether HSP90siRNA affects LCK/FYN activities, using LCK and 
FYN immunoprecipitates and in vitro phosphorylation of SAM68 (SRC-





associated in mitosis). TCR stimulation resulted in enhanced SAM68 
phosphorylation compared with control cells, confirming TCR-dependent 
activation of LCK and FYN in these experiments (Fig 2D). Similar to DEX 
treatment, LCK and FYN immunoprecipitated from HSP90siRNA-transfected 
cells did not have the capacity to phosphorylate SAM68, indicating that 
HSP90siRNA and DEX impair the enzymatic activities of LCK and FYN. These 
observations suggest that LCK/FYN-mediated TCR signalling depends on the 
presence of both HSP90 and GR. 
DEX or HSP90siRNA reduce GR–LCK/FYN localization 
Cellular localizations of GR, LCK and FYN were studied using confocal 
fluorescence microscopy. Double stainings for GR and LCK or GR and FYN 
demonstrated cytoplasmic staining of LCK, FYN and GR in quiescent cells 
(Fig 3). LCK, FYN and GR staining were mainly detected in the cell periphery 
on TCR stimulation (Fig 3, dotted lines). GR–LCK and GR–FYN cytoplasmic 
colocalization (indicated by yellow staining) was seen in quiescent cells, 
which was increased on TCR stimulation (Fig 3, solid lines). Reduced GR–
LCK and GR–FYN colocalization was observed in activated cells treated with 
DEX or HSP90siRNA (indicated by diminished yellow staining), which 
supports the immunoprecipitation data that DEX and HSP90siRNA disrupt 
GR–LCK and GR–FYN interactions. Owing to the small cytoplasm volume 
compared with the nuclear volume, no conclusions can be drawn about the 
precise cytoplasmic or membrane localization of LCK or FYN in the different 
conditions. Specificity controls for the immunofluorescent stainings are 







Figure 3.  
Dexamethasone and HSP90siRNA interfere with GR–LCK and GR–FYN 
colocalization. HSP90siRNA-transfected or nontransfected cells were 
pretreated with or without DEX (1 μM; 10 min) and activated with CD3 and 
CD28 antibodies (15 min). Cells were studied by confocal fluorescence 
microscopy and immunofluorescent double stainings of GR (fluorescein 
isothiocyanate-labelled, green) together with LCK or FYN 
(tetramethylrhodamine isothiocyanate-labelled, red) are shown. 
Cytoplasmic colocalization between GR and LCK or GR and FYN is indicated 
by yellow staining (solid lines). The nucleus was visualized with 4,6-
diamidino-2-phenylindole (not shown). Panels of optical cross-sections 
through T cells are depicted; scanned area for all images: 9 μm × 9 μm. 
Three independent experiments were performed and reproducible results 





were obtained. At least 20 cells under each condition were scanned, and 
representative cross-sections are indicated. DEX, dexamethasone; FYN, FYN 
oncogene related to SRC, FGR, YES; GR, glucocorticoid receptor; HSP90, 
heat-shock protein 90; LCK, lymphocyte-specific protein tyrosine kinase; 
siRNA, short interfering RNA. 
Discussion 
GCs mediate well-defined genomic effects through GR-dependent 
transcriptional changes. Clinical and experimental evidence for rapid 
nongenomic GC action have accumulated, but the underlying molecular 
mechanisms remain unexplained. Oestrogens can induce rapid signalling 
through intracellular transmembrane oestrogen receptors, providing 
evidence for nongenomic effects of steroids on cellular physiology 
(Revankar et al, 2005). Similarly, membrane-bound GRs have been 
identified in lymphocytes (Gametchu et al, 1999; Gametchu & Watson, 
2002) and in human peripheral blood mononuclear cells (Bartholome et al, 
2004), but their functional relevance remains unclear. It is known that, at 
high concentrations, GCs increase GR saturation in a dose-dependent 
manner, which intensifies the therapeutically relevant genomic GC 
activities (Buttgereit et al, 2002). Although saturation of cytosolic GRs is 
almost complete with 100 mg prednisone equivalent a day, the use of 
higher dosages (100–1,000 mg) is common and successful in daily clinical 
practice (Buttgereit et al, 2004), possibly as a consequence of nongenomic 
effects (Buttgereit et al, 1998). Nongenomic GC action is thought to be 
mediated through cytosolic or membrane-bound GRs and/or through 
nonspecific physicochemical interactions with membranes. 
Nongenomic GC-induced inhibition of LCK/FYN-mediated TCR signalling has 
been reported (Lowenberg et al, 2005), but the underlying mechanism 
remains unexplained. A relationship between GC stimulation and LCK/FYN 
kinases is supported by previous work, showing that prolonged DEX 
stimulation (enabling GC-induced genomic effects) disturbed the 
submembrane localization of LCK and FYN in murine T cells (Van Laethem 






contributes to these effects, but further studies are needed to clarify the 
role of GR and HSP90 in regulating TCR signalling. 
On the basis of the present work, we propose a model arguing that, in the 
absence of ligand, the GR sustains a TCR-associated complex containing 
HSP90, LCK and FYN (Fig 4). On GR–ligand binding, this membrane-bound 
multiprotein complex is dissociated, leading to a cellular redistribution of 
LCK and FYN and an inability of LCK/FYN to participate in TCR signalling. 
Our data show an essential role of HSP90 and GR in the formation of TCR-
associated protein complexes and in the regulation of efficient TCR 
signalling. Overall, these results provide new insight into the nongenomic 
mechanism of GC-induced immunosuppression in T cells. Selective 
inhibition of proximal TCR signalling through LCK/FYN presents 
opportunities for the development of novel immunosuppressive therapies. 
 
Figure 4.  





Model for nongenomic GC-induced immunosuppression in T cells. (A,B) On 
TCR ligation, LCK and FYN are recruited to the TCR complex, resulting in 
LCK/FYN kinase activation and initiation of downstream TCR signalling. The 
present study shows TCR-linked GR multiprotein complexes containing 
HSP90, LCK and FYN in activated T cells. (C,D) On GR–ligand binding, this 
multiprotein complex dissociates. (E) LCK and FYN are released from the 
TCR complex, leading to impaired TCR signalling as a consequence of a 
cellular redistribution and abrogated activation of LCK and FYN. FYN, FYN 
oncogene related to SRC, FGR, YES; GC, glucocorticoid; GR, glucocorticoid 
receptor; HSP90, heat-shock protein 90; LCK, lymphocyte-specific protein 
tyrosine kinase; TCR, T-cell receptor. 
Methods 
Cell culture. CD4+ T cells were purified from human peripheral blood 
mononuclear cells and maintained as described previously (Lowenberg et 
al, 2005). 
Reagents and antibodies. A complete list of the antibodies can be found in 
the supplementary information online. DEX and geldanamycin were 
obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
HSP90α/βsiRNA, GRsiRNA, control siRNA and SAM68 were purchased from 
Santa Cruz (Heidelberg, Germany). Kinase buffer and lysis buffer 
(supplemented with 1 μg/ml NaF, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 10 
mM Na3VO4, 1 mM pefabloc) were from Cell Signaling Technology 
(Beverley, CA, USA). 
Cell transfection. Cells were transfected by electroporation using routine 
procedures (Amaxa, Cologne, Germany). Each nucleofection sample 
contained 5 × 106 cells, 2 μg of highly purified siRNA and 100 μl of human 
T-cell Nucleofector. To determine transfection efficiency, green fluorescent 
protein (GFP)-tagged DNA (Amaxa) was used for electroporations, showing 
cells that were 40–50% GFP-positive 16 h after transfection, as assessed by 






Immunoprecipitation, in vitro kinase assay and immunoblotting. Cells were 
incubated at 37°C in six-well plates (5–10 × 106 cells/well) for 2 h followed 
by a 10 min pretreatment with 1 μM DEX dissolved in dimethyl sulphoxide 
(DMSO) or DMSO-supplemented media (control). Cells were subsequently 
activated for 15 min with CD3 antibodies (immobilized on plastic) and 
soluble CD28 antibodies (3 μg/ml). Cells were centrifuged (1,750 r.p.m., 10 
min), lysed in non-denaturing lysis buffer and subjected to 
immunoprecipitation followed by in vitro kinase assay and western 
blotting. The protocol for these procedures can be found in the 
supplementary information online. 
Fluorescent double stainings. After in vitro stimulations, cells were 
centrifuged for 5 min at 1,750 r.p.m. and pellets were resuspended in PBS. 
SuperFrost® plus microscope slides were pretreated with 0.01% poly-l-
lysine for 10 min, cell suspensions were subsequently incubated on the 
slides for 30 min (final concentration 2 × 105 cells/slide) and 3.7% 
paraformaldehyde was added for 30–60 min. Sections were washed in 
PBS/Triton X-100 0.1% (PBS-T), followed by a 1 h blocking step with 10% 
FCS in PBS-T. After overnight incubation with a GR antibody at 4°C, 
antibodies against LCK or FYN were added for 2–3 h. Slides were washed 
and incubated for 60 min with fluorescein isothiocyanate- and 
tetramethylrhodamine isothiocyanate-conjugated secondary antibodies 
(Heverlee, Belgium) diluted in 3% BSA/PBS-T. Alternatively, sections were 
incubated overnight at 4°C with an HSP90 antibody. Sections were 
mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) 
supplemented with 4,6-diamidino-2-phenylindole and sealed with 
coverslips. The protocol of the imaging technique can be found in the 
supplementary information online. 
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The glucocorticoid receptor is present in a T cell receptor (TCR) associated 
complex, which includes the Src family tyrosine kinase Lck. Glucocorticoids 
rapidly dissociate this complex resulting in the inhibition of canonical Lck-
phospholipase C (PLC)γ dependent TCR signaling. The relative importance 
of this nongenomic role of the GR compared to its direct transcriptional 
effects is not known. Superantigens induce a state of steroid resistance in 
activated T cells. It has been reported that in addition to canonical Lck-PLCγ 
signaling, superantigens can activate a noncanonical G protein-PLCβ 
dependent signaling pathway. Here we show that Staphylococcal 
Enterotoxin B (SEB) activates a Gαq and PLCβ2 dependent pathway in 
human T cells. We find that this pathway bypasses the need for canonical 
Lck-PLCγ signaling in T cell activation and renders superantigen stimulated 
T cells insensitive for glucocorticoids in vitro. We show that the PLCβ 
inhibitor U-73122 sensitizes SEB treated mice to dexamethasone in vivo. In 
conclusion, we find that effects of glucocorticoids on TCR induced T cell 
proliferation are mainly nongenomic and can be bypassed by the activation 







Glucocorticoids bind the glucocorticoid receptor, which subsequently 
dimerizes and translocates from the cytosol to the nucleus. The 
glucocorticoid receptor can bind to specific DNA sequences and alter the 
transcriptional activity of a wide range of genes many of which play a role 
in the immune system. However, the glucocorticoid receptor can also 
affect cell signaling in its DNA unbound state, so called non-genomic or 
non-transcriptional effects (1). We have previously found that the 
glucocorticoid receptor is present in a TCR associated complex that 
contains the Src-like tyrosine kinase Lck (2). Glucocorticoids rapidly 
dissociate the glucocorticoid receptor from this complex leading to the 
inactivation of Lck and downstream signaling pathways (2,3). Lck mediates 
canonical TCR signaling via activation of ZAP-70, phosphorylation of LAT 
and the assembly of a multiprotein complex. A key component of this 
complex is PLCγ which converts phosphatidylinositol 4,5-bisphosphate to 
inositol 3,4,5-triphosphate (IP3) and diacylglycerol (DAG). Generation of IP3 
activates Ca2+ signaling and leads to the nuclear translocation of nuclear 
factor of activated T-cells (NFAT) while DAG activates PKC and RAS-MAPK 
signaling (see Figure 1A) (4). Glucocorticoids inhibit T cell activation but the 
functional relevance of loss of TCR associated glucocorticoid receptor and 
the resulting inactivation of Lck versus transcriptionally mediated effects of 
the glucocorticoid receptor is not known. If the dissociation and 
inactivation of Lck is an important part of the mechanism of action of 
steroids this would predict that signals that bypass Lck render T cells 
relatively steroid insensitive.  
Superantigens activate T cells by directly cross linking MHC class II to the 
TCR as unprocessed proteins. Superantigens therefore bypass the 
specificity of conventional antigen recognition and can activate up to 20% 
of the total number of T cells (5). The massive activation of the adaptive 
immune system that ensues helps the pathogen to evade an appropriate 
immune response. The release of cytokines such as Il-1, TNFα, and IFNγ 
causes the signs and symptoms of toxic shock syndrome (6). Superantigen 
signaling is an excellent model to address the question of the relevance of 
glucocorticoid mediated inhibition of upstream T cell signaling. 
Superantigens have been described to cause steroid resistance in T cells 
(7). More importantly, it has previously been shown that superantigens can 
activate a noncanonical G protein-PLCβ signaling pathway in addition to 




canonical Lck-PLCγ signaling (8). If steroid mediated inhibition of T cell 
proliferation depends mainly on nongenomic inhibition of canonical T cell 
signaling, this predicts that superantigen mediated glucocorticoid 
resistance depends on PLCβ signaling.  
Here we find that superantigen mediated steroid resistance depends on 
Gαq mediated activation of PLCβ2 which bypasses dependence on Lck-
PLCγ signaling in primary human T cells in vitro. We go on to show the 
efficacy of glucocorticoid therapy in combination with a PLCβ inhibitor in a 
mouse model of toxic shock syndrome in vivo. These findings have 
implications for our understanding of the mechanism of action of 
glucocorticoids. They may point to novel therapeutic strategies to counter 
glucocorticoid resistance.   
Material and Methods 
Antibodies and Reagents 
The following antibodies were used: anti-Lck (3A5), anti-ß-Actin, anti-PLCß1 
(D-8), anti-PLCß2 (Q-15), anti-PLCß3 (C-20) and anti-pTyr (PY20) were 
purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-
phospho-Zap70 (Tyr319)/Syk (Tyr352), anti-phospho-Src (Tyr410), anti-
phospho-LAT (Tyr171) and the PI3 kinase inhibitor LY924002 were 
purchased from Cell Signaling Technology (Beverly, MA). Anti-PLCγ1 (2B1) 
was purchased from AbCam (Cambridge, USA). Anti-CD3 and anti-CD28 
were purchased from Sanquin (Amsterdam, The Netherlands). PMA, 
Ionomycin, SEB and the PLCß inhibitor U-73122 were purchased from 
Sigma-Aldrich (Zwijndrecht, The Netherlands). Phytohemagglutinin-M 
(PHA) was purchased from Roche (Mannheim, Germany). 
Mice 
Eight week old female C57BL/6 wild-type mice were purchased from Harlan 
(Boxmeer, The Netherlands) and housed in pathogen free conditions. All 
mice received a single intraperitoneal injection with a total volume of 500 
µl. Depending on the group they were in mice received 20 µg 
dexamethasone and/or 10 µg U-73122. All mice received 8.8 µl DMSO, 100 
µg SEB. 24 hours later the mice were euthanatized with carbon dioxide and 





Cytokine levels were determined using a Cytometric Bead Array (BD 
Bioscience, Breda, The Netherlands).  
Cell culture 
Human peripheral blood lymphocytes (PBL) were isolated from whole 
blood of healthy volunteers by Ficoll-Isopaque density gradient 
centrifugation. After washing monocytes were separated from 
lymphocytes by percoll density gradient centrifugation. The lymphocytes 
were cultured in IMDM (Gibco, Verviers, Belgium) supplemented with 10% 
heat inactivated fetal calf serum. For proliferation experiments cells were 
stimulated for 24 hours. In all experiments lymphocytes were stimulated 
with PHA (10 µg/ml), SEB (100 ng/ml) or a combination of PMA (10 ng/ml) 
and ionomycin (250 ng/ml). Proliferation was measured by 3H-thymidine 
incorporation assay. 
RNA extraction and quantitative RT-PCR 
Pelleted cells were dissolved in 500µl Trizol. After adding 250µl chloroform, 
tubes were spinned and the aqueous fase transferred. RNA was 
precipitated by adding 250µl isopropanol. RNA was washes in 70 Etoh, 
dried and dissolved in H20. For cDNA synthesis, 1 µg of RNA was 
transcribed using Revertaid (Fermentas). Quantitative RT-PCR was 
performed using SybrGreen (Qiagen) according to manufacturers’ protocol 
on a BioRad iCycler using specific primers for the mRNA of interest. 
Western blot 
Samples for Western blot were made by treating 5 ∙ 106 lymphocytes for 
10 minutes with 10 µM dexamethasone followed by 10 minutes 
stimulation. Cells were pelleted and lyzed in lysis buffer (0.1% NP40, 50 
mM Tris HCl, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 200 µM Na3VO4, 10 
mM NaF) containing protease inhibitors (Roche, Mannheim, Germany) for 
20 minutes on ice. Samples were spinned down, sample buffer was added 
to the supernatant and heated to 95 °C for 5 minutes, cooled on ice and 
sonicated. Samples were blotted overnight at 4°C in buffer containing 20% 
methanol on PVDF membrane (Millipore, Bedford, USA). The membrane 
was blocked with 5% BSA for 1 hour at RT followed by overnight incubation 
with the primary antibody at 4°C.  





For immunprecipitation experiments 10 ∙ 106 cells were used per 
condition. Cells were pelleted and lyzed as described above. The 
supernatant was precleared by adding 10 µl Protein A/G UltraLink resin 
(Pierce Biotechnology, Rockford, USA) for 30 minutes at 4°C. Beads were 
spinned down and discarded. Samples were incubated with 2 µg primary 
antibody and 25 µl beads for 2 hours at 4°C. Beads were washed with PBS, 
sample buffer was added and heated to 95°C for 5 minutes.   
Immunohistochemistry 
2 ∙ 105 PBMC were plated in a 12 wells plate. Cells were pretreated for 30 
minutes with 1 µM dexamethasone or with 0.5 µM U-73122 and then 
stimulated by adding SEB (100 ng/ml) for 1 hour. Thirty minutes before the 
end of the experiment cells were transferred to wells containing glass 
cover slips precoated with poly-L-lysine (0.01 (w/v) in H2O). The cells were 
fixed for 10 minutes in 4% paraformaldehyde at RT and stained for 1 hour 
at RT both primary and secondary antibody.  
siRNA transfection 
Two independent siRNAs targeting GNA11 (siRNA #1: 
CGACAAGAUCAUCUACUCAtt, siRNA #2: GCAUCAUCGAGUACCCUUUtt), 
GNAq (siRNA #1: UCGUCUAUCAUAGCAUUCCtg, siRNA #2: 
UAUCUUCAUCAGAGUAUCCtg) and PLCß2 (siRNA #1: 
GGCUACUACUUAUACUGGAtt, siRNA #2: CCAUGACCACAGACAUCUUtt) 
were purchased from Ambion Applied Biosystems (Austin, USA). 
Lymphocytes were transfected by electroporation using the Amaxa’s 
Nucleofector (Lonza, Cologne, Germany). Per condition 10 ∙ 106 
lymphocytes were electroporated according to protocol using 30 pmol 
siRNA and the Human T cell nucleofector kit for unstimulated T cells 
(Lonza, Cologne, Germany). After 4 hours the media was replaced. 
Experiments were performed 48 hours post transfection.  






Densitometric analysis of Western blot was performed using ImageJ 
(National Institute of Health, USA). Data were analyzed using Excel 
(Microsoft), FlowJo software (TreeStar, San Carlos, CA, USA) and Prism 
(GraphPad Software, La Jolla, USA) 
Results 
T cell activating signals that bypass Lck cause steroid resistance 
Glucocorticoids inactivate canonical TCR signaling by dissociating the 
glucocorticoid receptor from a TCR associated complex which contains Lck. 
This leads to inactivation of canonical TCR signaling including PLCγ. PLCγ 
plays a critical role in the activation of Ca2+ signaling and activation of PKC. 
To test the hypothesis that inhibition of T cell activation by glucocorticoids 
depends on inactivation of Lck, we used different T cell stimuli to test their 
relative sensitivity to glucocorticoid mediated inhibition of T cell 
proliferation. We used the plant lectin phytohemagglutinin (PHA) to 
strongly activate canonical, Lck dependent TCR signaling. PHA binds CD3 
directly and nonspecifically (9) resulting in the potential activation of all T 
cells. Treatment of primary human peripheral blood leukocytes (PBL) with 
10 µg/ml PHA resulted in a strong activation of T cell proliferation which 
was sensitive to treatment with the synthetic glucocorticoid analogue 
dexamethasone (Figure 1B, figure shows relative proliferation. Mean + 
standard error of absolute proliferation of PHA stimulated T cells without 
dexamethasone: 94214±7281 cpm). Next, we completely bypassed Lck 
signaling by direct activation of Ca2+ signaling with 250 ng/ml iononomycin 
and PKC with 10 ng/ml phorbol-12-myristate-13-acetate (PMA). Treatment 
with PMA/ionomycin resulted in complete resistance of proliferating T cells 
to dexamethasone even at very high doses (Figure 1B, Mean + standard 
error of absolute proliferation of PMA/ionomycin stimulated T cells 
without dexamethasone: 74154±1190 cpm). These results suggest that the 
inhibitory effects of glucocorticoids on T cell proliferation completely 
depend on a non-transcriptional role of the GR and may be related to 
inactivation of Lck. To further address this question we used the 
superantigen SEB. SEB not only activates canonical Lck-PLCγ signaling but 
has also been reported to activate a noncanonical G protein-
PLCβ−dependent signaling pathway (8). If effects of glucocorticoids depend 
on inhibition of Lck, this would predict that superantigen induced T cell 
proliferation is only partially responsive to glucocorticoids. The hypothesis 




would predict that G protein mediated activation of PLCβ is insensitive to 
effects of glucocorticoids and therefore still allows for PLCβ independent 
activation of Ca2+ signaling and activation of PKC (Figure 1A). Treatment of 
PBL with 100 ng/ml SEB resulted in an intermediated level of steroid 
resistance (Figure 1B, Mean + standard error of absolute proliferation of 
SEB stimulated T cells without dexamethasone:: 52633±1664 cpm). This is 
consistent with the hypothesis that glucocorticoids inhibit SEB induced 
activation of Lck-PLCγ signaling but not G protein-PLCβ signaling.  
To examine if glucocorticoids indeed inactivate both PHA and SEB 
mediated activation of Lck and canonical TCR signaling we added 10 µM 
dexamethasone to PHA and SEB stimulated PBL and determined 
phosphorylation of Lck and downstream signaling mediators ZAP70, LAT 
and PLCγ. This experiment showed that dexamethasone inhibits both PHA 
and SEB mediated Lck signaling (Figure 1C). This suggests that SEB induced 
steroid resistance involves a bypass of the need for Lck-PLCγ signaling in T 
cell activation. 
We previously reported that treatment with dexamethasone causes the 
disruption of a TCR associated complex which contains both LCK and the 
glucocorticoid receptor (2,3). To investigate if a similar mechanism is 
responsible for the inhibition of SEB stimulated signal transduction, PBL 
were stimulated with SEB and treated with dexamethasone. LCK was 
immunoprecipitated and the interaction with the GR was analyzed on 
Western blot (Figure 1D). Stimulation of PBL with SEB results in the 
recruitment of the GR to LCK. In line with previous findings dexamethasone 






Figure 1. Signals that bypass canonical Lck-PLCγ signaling render T cells resistant 
to glucocorticoids. (A) A schematic overview of the canonical Lck-PLCγ dependent 
signaling pathway and the alternative PLCβ signaling route that is activated by SEB. 
(B) Dexamethasone mediated inhibition of T cell proliferation induced by different 
stimuli. PBL isolated from whole blood were stimulated for 24 hours with PHA (10 
µg/ml), SEB (100 ng/ml) or a combination of PMA (10 ng/ml) and ionomycin (250 
ng/ml). Proliferation was measured by 3H-thymidine incorporation assay. PBL 
stimulated with PHA are more sensitive to treatment with dexamethasone than 
PBL stimulated with SEB. Stimulation with a combination of PMA/ionomycin 
causes total steroid insensitivity. (C) Dexamethasone inhibits both PHA and SEB 
mediated phosphorylation of components of the canonical Lck-PLCγ dependent 
signaling pathway.  The figure shows Western blot analysis of PBL pretreated for 
10 minutes with 10 µM dexamethasone followed by 10 minutes of stimulation 




with PHA (10 µg/ml) or SEB (100 ng/ml). Each lane represents the same sample 
analyzed for different proteins. Bar graphs on the right of each blot represent 
densitometric analysis of the relative phosphorylation of dexamethasone treated 
PBL are given relative to SEB and PHA stimulation without dexamethasone. (D) 
Interaction of the glucocorticoid receptor (GR) with LCK. PBL were stimulated with 
SEB (100 ng/ml) for one hour and Lck was immunoprecipitated with a specific 
antibody. Immunoblots for the GR show that the GR associates with Lck upon 
stimulation with SEB. Concurrent treatment with dexamethasone (10 µM) reduces 
the interaction between LCK and the GR. An immunoblot for LCK was used as a 
loading control. 
SEB induced steroid resistance depends on PLCβ signaling 
To investigate if activation of PLCβ by SEB is responsible for the relative 
insensitivity to dexamethasone we used the PLCβ inhibitor U73122 (10). 
Treatment of SEB stimulated PBL with either U73122 (0.5 µM) or 
dexamethasone (10 µM) partially inhibited SEB induced T cell proliferation. 
Combination of dexamethasone with U73122 showed an additive effect on 
T cell proliferation (Figure 2A, P < 0.001 for dexamethasone versus 
dexamethasone + U73122) suggesting that both inactivate independent 
signaling pathways. This experiment strongly suggests that SEB induced 
activation of PLCβ partially bypasses inhibitory effects of glucocorticoids on 
Lck-PLCγ signaling. We therefore used nuclear translocation of NFAT1 as a 
read out of downstream TCR signaling. NFAT1 is translocated to the 
nucleus of activated T cells downstream of PLC mediated Ca2+ signaling 
(11). If activation of PLCβ bypasses glucocorticoid mediated inhibition of 
Lck-PLCγ signaling this would predict that dexamethasone only partially 
prevents NFAT1 translocation in SEB treated PBL and that inhibition is 
complete if dexamethasone is combined with U73122. We found that PHA 
mediated NFAT1 translocation was very sensitive to dexamethasone. In 
contrast, dexamethasone only partially prevented nuclear translocation of 
NFAT1 in SEB treated PBL and translocation was completely prevented by 
dexamethasone/U73122 combination treatment (Figure 2B and C, P < 






Figure 2. PLCβ inhibitor U73122 prevents SEB mediated glucocorticoid resistance. 
(A) Effect of dexamethasone, PLCβ inhibitor U73122 and combination treatment 
on SEB induced T cell proliferation. PBL were stimulated with SEB (100 ng/ml) for 
24 hour in the presence or absence of inhibitors as indicated. Proliferation was 
analyzed by 3H-thymidine incorporation assay. (B) Effect of various treatments on 
nuclear translocation of NFAT1. PBL were pretreated for 30 minutes with 1 µM 
dexamethasone or with 0.5 µM U-73122 followed by 1 hour of SEB (100 ng/ml) 
stimulation. NFAT1 localization was visualized by immunohistochemistry. Each bar 
represents the average percentage of cells with nuclear NFAT1 staining as counted 
per three images at 200x magnification. (C) Representative images of NFAT1 
staining. In the proportion of SEB sensitive lymphocytes stimulation with SEB 
causes NFAT1 to translocate to the nucleus which is visible as a bright green 
staining locate at the nucleus. Values in A and B are mean ± standard error, * = P < 
0.05, *** = P < 0.001.            
SEB causes steroid insensitivity through PLCß2  
It has previously been shown that SEB activates PLCβ1 in the Jurkat T cell 
line. To determine which isoform of the PLCβ family is responsible for the 
SEB induced steroid insensitivity in primary human lymphocytes we used 
Western blot to visualize the different PLCβ isoforms that are expressed in 
human T cells (Figure 3A). In contrast to Jurkat cells, primary human T 




lymphocytes express PLCβ2 rather than PLCβ1 and express low levels of 
PLCβ3. To examine if activation of PLCβ2 is responsible for SEB induced 
steroid resistance we knocked down PLCβ2 in PBL using two different 
siRNAs (Figure 3B). Indeed, knocking down PLCβ2 levels reduces SEB 
induced proliferation and restores steroid sensitivity in primary human PBL 
to levels similar to PBL stimulated with PHA (Figure 3C. Figure shows 
relative proliferation. Mean ± standard error for absolute proliferation; 
PHA: 23137 ± 397, SEB (control siRNA): 16570 ± 1155). These results show 
that PLCβ2 is the predominant isoform expressed in primary human PBL 
and support the hypothesis that SEB bypasses glucocorticoid mediated 






Figure 3. SEB mediated glucocorticoid resistance is PLCβ2 dependant. (A) 
Expression of PLCβ and different PLCβ isoforms in human CD4 T cells, Jurkat cells, 
3T3-L1 and HEK293 cells indicates that PLCβ2 is the predominant isoform 
expressed in primary human T cells. The figure shows Western blot analysis of the 
presence of the different isoforms in samples with an equal amount of total 
protein from different cell types. (B) Western blot showing the efficiency of the 
two PLCβ2 siRNAs in knocking down PLCβ2 compared to cells transfected with 
control siRNA. (C) The figure shows the effect of dexamethasone and PLCβ2 siRNAs 
on SEB mediated proliferation compared to the effect of dexamethasone on PHA 
mediated proliferation. Cells were transfected with siRNA and allowed to recover 
for two days before stimulation and dexamethasone treatment. Proliferation was 
measured after 24 hours of treatment by 3H-thymidine incorporation assay. 
Values in C are mean ± standard error, * = P < 0.05, ** = P < 0.01. 
SEB induced steroid resistance depends on activation of Gαq 
PLCß is activated by members of the Gαq family of G proteins (12) such as 
Gα11 (13) and Gαq (14). It was previously suggested that Gα11 acts 
upstream of PLCβ activation in Jurkat T cells (8).  We first used quantitative 
RT-PCR to examine expression of both Gαq and Gα11 in Jurkat cells and 
primary human CD4+ T lymphocytes using testis as a positive control for 
G 11 and monocytes as a positive control fo  αq (Figure 4A). This howed 
that Gαq is the predominant Gα isoform expressed in both Jurkat cells and 
primary human T lymphocytes. 
To further elucidate which G protein is involved in SEB stimulated ΠΛΧβ2 
activation we transfected PBL with siRNA targeting Gα11 or Gαq. Knock 
down efficiency of both Gαq and Gα11 was determined by quantitative RT-
PCR (Figure 4B). Consistent with the low expression of Gα11 in primary 
human T cells, siRNA against Gα11 did not affect proliferation in SEB 
stimulated PBL (Figure 4C, figure show relative proliferation, mean ± 
standard error for absolute proliferation; PHA only: 13271 ± 782, SEB only 
control siRNA: 9199 ± 459). In contrast, siRNA against Gαq reduced SEB 
induced proliferation showing that SEB induced proliferation partially 
depends on Gαq signaling. This suggests that Gαq and not Gα11 acts 
upstream of PLCβ2 in primary human T cells. Gaq siRNA sensitized SEB 
treated cells to treatment with dexamethasone. This is consistent with a 
role for Gαq signaling in mediating SEB induced steroid resistance.  
 




Figure 4. SEB mediated glucocorticoid resistance depends on Gαq signaling. (A) 
Quantitative RT-PCR for Gα11 and Gαq in primary human CD4+ cells and Jurkat 
cells using testis and monocytes as respective positive controls. (B) Knock down 
efficiency of Gα11 and Gαq in PBL as measured by quantitative RT-PCR. (C) The 





compared to the effect of dexamethasone on PHA mediated proliferation. Cells 
were transfected with siRNA and allowed to recover for two days before 
stimulation and dexamethasone treatment. Proliferation was measured after 24 
hours of treatment by 3H-thymidine incorporation assay. Values are mean ± 
standard error, ** = P < 0.01, *** = P < 0.001. 
SEB treated mice are responsive to dexamethasone-PLCβ inhibitor 
combination treatment 
To test if SEB induced PLCβ activation is responsible for the relative 
inefficacy of glucocorticoids in the treatment of toxic shock syndrome we 
injected mice with SEB and treated them with either dexamethasone (20 
µg/mouse, ~1 mg/kg) or U73122 (10 µg/mouse, ~0.5 mg/kg) alone or the 
combination of both. Mice were injected with 100 µg SEB intraperitoneally. 
In the same injection mice received solvent, 20 µg dexamethasone 
(approximately 1 mg/kg), 10 µg U-73122 or combination treatment.  We 
measured the serum levels of Tnfα, Il-6 and Ifnγ at 8 and 24 hours after 
treatment (Figure 5A,B) and spleen weight (Figure 5C) at 24 hours as a read 
out of the response to treatment. Treatment with dexamethasone had 
little effect on serum cytokines. Dexamethasone did not significantly affect 
cytokine production at 8 hours after treatment and only IFNγ was 
significantly reduced at 24 hours. Treatment with U-73122 did not affect 
serum cytokine production at either time point. In contrast, 
dexamethasone/U-73122 combination treatment significantly reduced 
production of all three cytokines at both time points. The same effect was 
seen for spleen weight. These data show that U-73122 sensitizes SEB 
treated mice to treatment with dexamethasone.  




Figure 5. The PLCβ inhibitor U73122 sensitizes SEB injected mice to treatment 
with dexamethasone. (A) Serum cytokine levels at 8 hours after treatment with 
SEB. (B) Serum cytokine levels at 24 hours after treatment with SEB.  (C) Spleen 
weights. Values are mean ± standard error, * = P < 0.05, ** = P < 0.01. 
Discussion 
The glucocorticoid receptor has long been thought to exert its effects 
primarily through the transcriptional control of glucocorticoid target genes. 
In past years it has become increasingly clear that the glucocorticoid 
receptor also has a non-transcriptional role in modulating cellular signal 
transduction. Recently we have shown that in the absence of ligand, the 
glucocorticoid receptor is associated with the TCR complex. Glucocorticoids 
dissociate the receptor from the TCR complex leading to rapid inactivation 
of Lck, the kinase that activates canonical PLCγ dependent TCR signaling 
(2,3). Glucocorticoids are potent inhibitors of T cell proliferation but the 





complex or transcriptional regulation had not been determined. Here we 
show that T cells can be made completely steroid resistant by directly 
activating T cells at a level downstream of PLCγ1 by stimulating them with 
PMA (activates PKC) and ionomycin (activates Ca2+ signaling). This shows 
that glucocorticoids act at a level upstream of activation of PKC and Ca2+ 
signaling (Figure 6). 
 
Figure 6. A model of SEB induced steroid resistance in primary human T cells. 
Canonical Lck-PLCγ signaling is inhibited by dexamethasone at the level of Lck. This 
inhibitory effect of glucocorticoids can be completely bypassed by downstream 
activation of TCR signaling at the level of Ca2+ (ionomycin) and PKC (PMA) 
signaling. SEB causes partial steroid resistance by activating dexamethasone 
sensitive Lck-PLCγ signaling in addition to dexamethasone insensitive Gαq-PLCβ2 
signaling. Combination of dexamethasone with siRNA against Gαq, PLCβ2 or 
U73122 effectively blocks SEB induced T cell proliferation as it blocks both 
pathways.   
If glucocorticoids act at the level of Lck-PLCγ signaling this would predict 
that signals that bypass this signaling route may render cells partially 




steroid resistant. This is why we examined the effect of glucocorticoids on 
SEB mediated T cell activation. It was previously described that SEB 
activates PLCβ dependent signaling in a Jurkat T cell line in addition to Lck-
PLCγ signaling (8). This is why we determined if this PLCβ mediated bypass 
of Lck-PLCγ signaling is responsible for SEB induced steroid insensitivity that 
had previously been described in human PBMC (7). We find that primary 
human PBL express primarily PLCβ2. Inhibition of PLCβ signaling with 
U73122 or specific depletion of PLCβ2 both reduced SEB mediated T cell 
proliferation. A combination of PLCβ inhibition plus dexamethasone 
completely inhibited T cell proliferation. Thus the partial steroid 
insensitivity of SEB treated T cells is dependent on PLCβ signaling. This 
shows that effects of glucocorticoids on T cell proliferation are dependent 
on inhibition of PLCβ dependent signaling. Thus effects of glucocorticoids 
on T cell proliferation are largely dependent on non-transcriptional effects 
of the glucocorticoid receptor. 
PLCβ signaling is often activated by members of the guanine binding 
protein family. It has previously been shown that SEB activated PLCβ 
signaling in Jurkat T cells is pertussis toxin insensitive and mediated by 
Gα11. We confirmed that SEB mediated T cell proliferation is pertussis 
toxin insensitive in human PBL (not shown). However, we find very low 
levels of Gα11 that in primary human PBL. They express high levels of the 
closely related family member Gαq instead. Indeed, depletion of Gαq but 
not Gα11 reduced SEB mediated proliferation and restored glucocorticoid 
sensitivity. This suggests that Gαq acts upstream of PLCβ2 in primary 
human PBL. 
The mechanism of action of SEB mediated steroid insensitivity may not 
only be relevant as a model to study genomic versus nongenomic 
glucocorticoid signaling but also help to improve therapy for patients with 
toxic shock syndrome. These patients receive mainly supportive therapy as 
no specific treatment exists. Corticosteroids are not recommended for 
toxic shock syndrome (see www.uptodate.com) as clinical evidence for 
their efficacy is lacking and a single small retrospective study showed that 
steroids may alleviate some symptoms of TSS but do not affect mortality 
(15). The limited efficacy of glucocorticoids in toxic shock syndrome is likely 
related to the fact that superantigens induce steroid resistance and 
mechanisms to alleviate this may help to improve therapy. Indeed, we find 





dexamethasone or the PLCβ inhibitor U73122. This may in part be 
explained by the dosage U73122 used in this experiment which, compared 
to other studies, is relatively low (16,17). However 
dexamethasone/U73122 combination treatment significantly reduced 
cytokine production in SEB treated mice. A caveat of the in vivo study is 
that we did not directly assess measures of T cell activation, it cannot be 
excluded that the observed effects of dexamethasone and U73122 are 
partially explained by effects on innate immune cells such as monocytes or 
macrophages. Our in vitro studies suggest however that the effects may be 
directly on TCR signaling.  
In conclusion, we find that SEB activates a Gαq-PLCβ2 dependent signaling 
pathway that bypasses Lck-PLCγ signaling. Inhibition of this PLCβ signaling 
pathway restores glucocorticoid sensitivity to SEB activated T cells. This 
strongly indicates that glucocorticoid mediated inhibition of T cell 
proliferation is dependent on inhibition of Lck-PLCγ signaling. Our data 
suggest that dual PLCβ/γ inhibitors or glucocorticoid/PLCβ inhibitor 
combination therapy may be useful in the treatment of TSS.    
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The use of glucocorticoids as immunosuppressives is limited by important 
side effects such as induction of adipogenesis and development of muscle 
atrophy.  Glucocorticoids bind to the glucocorticoid receptor (GR) resulting 
in the formation of a homodimer that translocates from the cytosol to the 
nucleus. In the nucleus these dimers bind to glucocorticoid response 
elements (GRE) on the DNA and mediate both transactivation and 
transrepression of target genes. In addition to this transcriptional 
regulation of cellular phenotype, there are also more rapid, non-
transcriptionally mediated effects of glucocorticoids. We have previously 
shown that the GR is part of the T cell receptor (TCR) complex and that 
ligand binding results in dissociation of the GR from this complex and 
inhibition of canonical TCR signaling through LCK-PLCγ.1, 2 The dissociation 
of this complex appears to play an important role in glucocorticoid 
mediated inhibition of T cell activation as stimuli that bypass LCK-PLCγ-
signaling render T lymphocytes glucocorticoid resistant.3 Here we aimed to 
develop a GR ligand that inactivates LCK-PLCγ-signaling without resulting in 
transcriptional regulation. Potential steroidal and non-steroidal candidates 
were identified using an in silico docking assay to predict GR affinity. 
Selected compounds where screened in in vitro for GRE mediated 
transcriptional regulation and their capacity to inhibit T cell activation. This 
approach led to the discovery of compounds S3.1 and S3.4, which lack a 
generic cortisol structure but bind the GR in T lymphocytes and inhibit LCK-
PLCγ-dependent T cell proliferation without causing transcriptional 
modulation of GR target genes. In contrast to classical glucocorticoids, S3.1 
and S3.4 do not induce adipogenesis and do not cause muscle cell atrophy 
in vitro. Our data show that it is possible to develop non-steroidal GR 
ligands that dissociate transcriptional from non-transcriptional effects and 






We started our search for a non-transcriptionally acting GR ligand with two 
rounds of in silico screening. In the first round, we identified ~18,000 
steroidal and ~230,000 non-steroidal compounds based on their similarity 
to the structure of cortisol or gonane respectively. In the second round 
these compounds were virtually docked into the binding pocket of the GR 
in two distinct conformations and assigned a score that reflected their 
predicted binding potency. The top 30 steroidal and 50 non-steroidal 
compounds with the highest scores were then further screened using two 
in vitro assays. The first assay consisted of HEK-293 cells stably transduced 
with a GRE-luciferase construct to determine if the compounds were 
capable of inducing GR-dependent transcriptional regulation. To measure 
the ability of the compounds to inhibit T cell proliferation, primary human 
peripheral blood lymphocytes (PBL) were stimulated with 
phytohemagglutinin (PHA) or Staphylococcus aureus enterotoxin B (SEB) in 
the presence of 10 μM of each compound and proliferation was measured 
using a tritiated thymidine incorporation assay. PHA binds CD3 and 
activates canonical LCK-PLCγ signaling which can be almost completely 
inhibited by glucocorticoids.4 In contrast, SEB activates both canonical TCR 
dependent LCK-PLCγ signaling and a non-canonical G protein-PLCβ 
dependent signaling pathway, which renders SEB stimulated lymphocytes 
partially steroid resistant.3 We were therefore looking for a compound that 
would inhibit PHA dependent proliferation to a greater extent than SEB 
mediated proliferation. This strategy (for results of all compounds see 
Extended Data Table 1) resulted in the identification of two non-steroidal 
compounds, S3.1 and S3.4 (Fig. 1a-d) which did not result in GRE-mediated 
transactivation and inhibited PHA mediated proliferation to a greater 
extent than SEB mediated proliferation (Fig.  1e). To confirm binding of 
S3.1 and S3.4 to the GR, we performed a competition assay using 
[3H]dexamethasone in human PBL (Fig. 1f). This showed that both 
compounds are low affinity ligands for the GR. The dose-response curve for 
inhibition of PHA mediated lymphocyte proliferation of both compounds 
was much lower than high affinity ligand dexamethasone but similar to 
that of hydrocortisone (Fig. 1g).  




Figure 1. Identification of S3.1 and S3.4 as low affinity GR ligands that lack 
transcriptional activation but suppress T cell activation. a, structure formula 
of S3.1. b, 3D representation of S3.1 binding to the GR. c, structure formula of 
S3.4. d, 3D representation of S3.4 binding to the GR. e, HEK-293 cells stably 
transduced with a GRE-luciferase construct were treated with dexamethasone 
(Dex, 10 µm), S3.1 (10 µm) or S3.4 (10 µm), luciferase production (yellow bars) is 
shown relative to dexamethasone. Human PBL were treated with PHA (10 mg/ml, 
blue bars) or SEB (100 ng/ ml, red bars) in the presence or absence of 
dexamethasone, S3.1 and S3.4 and T cell proliferation was measured using 
tritiated thymidine, data are relative to PHA/SEB stimulated PBL in the absence of 
compound. f, competition assay using [3H]dexamethasone in whole human PBL.  
S3.1 and S3.4 show low affinity for the GR compared to both dexamethasone (Dex) 
and hydrocortisone (HC). g, proliferation of PHA (10 mg/ml) stimulated human PBL 
relative to no compound in the presence of a concentration range of 
dexamethasone (Dex), hydrocortisone (HC), S3.1 and S3.4. Data in e-g are mean 
and standard error. *** = P < 0.001. 
We previously found that the chaperone HSP90 is specifically complexed 
with both LCK and the GR in activated T cells in the absence of GR ligand. 





inhibition of signaling downstream of LCK. We found that both S3.1 and 
S3.4 inhibited of the phosphorylation of downstream LCK signaling targets 
ZAP70 and LAT similar to dexamethasone (Fig. 2a). To examined if S3.1 and 
S3.4 would disrupt the interaction between the GR and LCK we performed 
an immunoprecipitation experiment on the endogenous proteins in 
primary human PBL. Immunopreciptation of GR showed that treatment of 
PBL with PHA resulted in increased interaction between the GR and LCK, 
this interaction was disrupted by dexamethasone as well as S3.1 and S3.4 
(Fig 2b). Dissociation by S3.4 was as potent as that induced by 
dexamethasone. We next determined if S3.1 and S3.4 would also dissociate 
LCK from the chaperone HSP90, again by immunoprecipitating the 
endogenous proteins in PHA treated primary human PBL. Treatment with 
PHA increased the interaction between LCK and HSP90, which was reduced 
by both compounds (Fig. 2c). Again the dissociation induced by S3.4 was as 
potent as that induced by dexamethasone. Immunoprecipitation of LCK 
flowed by Western blot for HSP90 gave the same results (Fig. 2d).  
 
Figure 2. S3.1 and S3.4 dissociate the HSP90-GR-LCK complex. a, 
Dexamethasone (10 µm), S3.1 (10 µm) and S3.4 (10 µm) inhibit phosphorylation of 
downstream TCR signaling targets ZAP70 and LAT in PHA stimulated human PBL. b, 




Immunoprecipitation of the GR in CD3/CD28 stimulated human PBL shows that 
dexamethasone (Dex, 10 µm), S3.1 (10 µm) and S3.4 (10 µm) dissociate the 
interaction of the GR and LCK in activated T cells. c, Immunoprecipitation of HSP90 
in PHA stimulated human PBL shows that dexamethasone (Dex, 10 µm), S3.1 (10 
µm) and S3.4 (10 µm) dissociate the interaction of the HSP90 and LCK in activated 
T cells. d, immunoprecipitation of LCK shows the same results.  
Since both S3.1 and S3.4 do not induce GRE-mediated transcriptional 
modulation, we examined if the compounds induced nuclear translocation 
of the GR. We transiently transfected HCT116 cells that express no 
detectable GR, with a GFP labeled GR. Dexamethasone induced a potent 
nuclear translocation of the GR as expected (Fig. 3a). Of the two 
compounds, only S3.4 induced a modest level of nuclear translocation in 
GR-GFP transfected cells. This result was confirmed by detecting 
endogenous GR expression by Western blot in Hela cells after isolating 
nuclear and cytosolic fractions (Fig. 3b,c).   Phosphorylation of residues 
near the N terminus of the GR such as serine 211 (S211) is important to 
regulate its transcriptional activity.5 To investigate the phosphorylation 
status of the GR receptor at S211 after treatment, lysates from Hela cells 
were analyzed on Western blot (Fig. 3d). Treatment with neither S3.1 nor 
with S3.4 causes the GR to become phosphorylated. Similar results were 





Figure 3. S3.1 and S3.4 do not cause nuclear translocation of 
phosphorylation of the GR. a, HCT116 cells were transfected with a GFP tagged 
GR and treated with either dexamethasone (Dex, 10 µm), S3.1 (10 µm) or S3.4 (10 
µm). The localization of the GR was examined by immunofluoresence. b, Hela cells 
were treated with dexamethasone (Dex, 10 µm), S3.1 (10 µm) or S3.4 (10 µm) and 
the localization of the GR was determined by western blot in nuclear and cytosolic 
extracts. c, densiometric analysis of nuclear translocation of the GR in Hela cells as 
determined by western blots of three independent experiments. d, 
phosphorylation of the GR in Hela cells treated with dexamethasone, S3.1 and 
S3.4. e, phosphorylation of the GR in CD3/CD28 stimulated human PBL treated 
with dexamethasone, S3.1 and S3.4. 




Thus, S3.1 and S3.4 are low affinity nonsteroidal GR ligands that inhibit T 
cell proliferation by dissociating the HSP90-LCK interaction without 
inducing nuclear translocation of the GR. It is not known to what extent 
side effects such as adipogenesis and muscle atrophy are dependent on 
non-transcriptional or transcriptional effects of the GR. We therefore 
examined the capacity of S3.1 and S3.4 to induce adipogenesis in 3T3-L1 
cells, a well-established model of glucocorticoid induced adipogenesis. In 
these cells treatment with dexamethasone causes adipocyte formation 
that can be detected by significant accumulation of fatty acids in 
intracellular vacuoles (Fig. 4a,b). In contrast, treatment with S3.1 or S3.4 
did not induce any adipogenesis at all.  
Glucocorticoid induced muscle atrophy is caused by loss of muscle fiber 
thickness due to transactivation of myostatin, a negative modulator of 
skeletal muscle. To test if treatment with S3.1 or S3.4 caused a reduction in 
the diameter of muscle fibers a C2C12 myotube model was used. After 
establishment of the myotubes in culture, the cells were treated for 24 
hours with S3.1, S3.4 or dexamethasone. Treatment with dexamethasone 
reduced the diameter of the myotubes significantly while treatment with 
S3.1 or S3.4 did not affect the myotubes and diameters remained 





Figure 4. S3.1 and S3.4 do not induce adipogenesis and do not cause 
myotube atrophy. a, 3T3-L1 cells treated with dexamethasone (Dex, 10 µm), 
S3.1 (10 µm) or S3.4 (10 µm). b, quantification of induction of adipogenesis 
measuring oil red O positive pixels per high powerfield (200x magnification) using 
ImageJ software (n=4 per condition). c, quantification of muscle fiber thickness (n 
>250 per condition) in C2C12 cells treated with dexamethasone (Dex, 10 µm), S3.1 
(10 µm) or S3.4 (10 µm). d, muscle fibers of C2C12 cells visualized using 
glutaraldehyde induced autofluorescence. Data in b and c are mean and standard 
error. *** = P < 0.001. 
All steroid hormones have rapid non-transcriptionally mediated effects in 
addition to their classical transcriptionally mediated cellular responses.6 
We have previously shown that glucocorticoids inhibit TCR signaling non-
transcriptionally by dissociating a TCR associated complex that contains 




HSP90, LCK and the GR.1-3, 7 Thus far it has not been possible to determine if 
non-transcriptionally mediated GR dependent effects are sufficient to 
cause inhibition of T cell signaling. Also, since no compounds were available 
thus far to specifically induce non-transcriptional GR mediated effects it 
was not known if side effects such as adipogenesis and muscle cell atrophy 
were dependent on transcriptional or non-transcriptional effects of 
glucocorticoids. The findings presented here show that it is possible to 
design GR ligands that specifically dissociate the GR from its cytosolic 
complex with HSP90 and LCK without causing phosphorylation or nuclear 
translocation of the GR. Such compounds therefore lack any of the 
transcriptionally mediated effects of GR bound by classical agonists such as 
dexamethasone that cause potent phosphorylation and nuclear 
translocation of the GR. The identification of S3.1 and S3.4 as non-
transcriptionally acting GR ligands has allowed us to demonstrate that such 
compounds inhibit TCR signaling and T cell proliferation without causing 
effects on adipogenesis or myotube thickness in established in vitro models 
of these glucocorticoid induced side effects. Our approach shows that it is 
possible to dissociate GR mediated immunosuppression from unwanted 
side effects by generating ligands that dislocate the GR from the HSP90 
complex but fail to induce nuclear translocation. 
Material and Methods 
In silico compound screen 
We screened 9.2 million publically available compounds from the Zinc 
database (http://zinc.docking.org) in October 2009. In order to enhance 
the chance of finding chemicals with the desired effect we worked in 
parallel with two sets of compounds. The first set consisted of steroidal 
compounds that contained the four conjugated rings of cortisol (Extended 
data Fig. 1a), other naturally occurring steroid hormones (Extended data 
Fig. 1b,c) or synthetic GR agonists such as dexamethasone possessing two 
double bonds in the first ring (Extended data Fig. 1d). An exact match of a 
compound with the query skeleton was used as a selection criterion 





set of compounds comprised molecules that share some similarity to 
gonane which was quantified using the LINGO method that has been 
previously described8 and has been implemented in the OEChem Tool Kit 
(OpenEye Scientific Software, Inc., Santa Fe, NM, USA). This second set 
consisted of a further ~230,000 non-steroidal compounds.   
In the next round of in silico screening, all compounds selected in the first 
round were virtually docked to the GR binding pocket using the glide mode 
of the Schrödinger program suite (Schrödinger, LLC, New York). To cover 
the different conformational spaces in which the compounds could be 
docking we used four different structures of the GR (to be found at Protein 
Data Bank http://www.rcsb.org/pdb/home/home.do, under IDs 1M2Z, 
1P93, 1NHZ and 3BQD). Structures 1M2Z and 1P93 describe the GR in a 
state bound by dexamethasone. Another 2 structures (1NHZ, 3BQD) 
describe the GR bound by an antagonist.  
Compounds were finally sorted according to their Z-score values that 
reflect the probability of binding to the receptor. In order to test 
compounds capable of binding both known conformational states of the 
GR we selected the top 30 steroidal compounds and the top 50 non-
steroidal compounds in each conformation for in vitro testing, resulting in a 
total of 80 compounds (Extended Data Table 1). 
Antibodies and Reagents 
Dexamethasone, hydrocortisone, IBMX, insulin, oil red O, glutaraldehyde 
and SEB were purchased from Sigma Aldrich (Zwijndrecht, The 
Netherlands). Luciferase was purchased from Promega (Leiden, The 
Netherlands). PHA (PHA-M), phalloidin, SlowFade® Gold Antifade Reagent 
with DAPI and horse serum was purchased from Life Technologies 
(Bleiswijk, The Netherlands).  Human anti-CD3 and anti-CD28 were 
purchased from Sanquin (Amsterdam, The Netherlands). Anti-phospho-GR 
(Ser211) #4161, anti-phospho-Zap70 (Tyr319)/Syk (Tyr352) #2701 and anti-
phospho-LAT (Tyr171) #3581 were purchase from Cell Signaling 
Technologies (Leiden, The Netherlands). Anti-Actin (I-19) (sc-1616-R), 
HSP90α/β (H-114) (sc-7947), HSP 90α/β (N-17) (sc-1055), Lck (2102) (sc-




13), Lck (3A5) (sc-433), GR (E-20) (sc-1003) and GR (P-20) (sc-1002) were 
purchased from Santa Cruz Biotechnology (Heidelberg, Germany). 
Cell Culture 
Human PBLs were isolated from whole blood of healthy volunteers by 
ficoll-isopaque density-gradient centrifugation. After washing, monocytes 
were separated from lymphocytes by percoll density-gradient 
centrifugation. The lymphocytes were cultured in IMDM (Life Technologies, 
Verviers, Belgium) supplemented with 10% heat-inactivated FCS. For 
measurements of cell proliferation, cells were stimulated for 24 h. In all 
experiments, lymphocytes were stimulated with PHA (10 mg/ml) or SEB 
(100 ng/ ml). Proliferation was measured using a [3H]thymidine-
incorporation assay.  
Glucocorticoid mediated transactivation was measured in HEK293 cells 
stably transduced with a luciferase gene behind a glucocorticoid responsive 
element (Panomics, Milano, Italy). The cells contain Luciferase activity was 
measured using the Luciferase Assay System from Promega (Leiden, the 
Netherlands) according to the manufacturers protocol. 
Localization of the GR was investigated by transiently transfecting HCT116 
colorectal cancer cells with a GR-GFP fusion construct using lipofectamine 
(Life Technologies, Bleiswijk, the Netherlands). Measurements of GR in 
nuclear fractions was performed in Hela cells. HCT116 and Hela cells were 
cultured in Dulbecco's Modified Eagle Medium (Life Technologies, Verviers, 
Belgium) supplemented with 10% heat-inactivated FCS.  
Induction of adipogenesis was determined in 3T3-L1 mouse fibroblasts. 
Two days after the cells reached confluency the medium was replaced by 
DMEM containing 10% FCS, 1.6 µM insulin, 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX) and either 0.25 µM dexamethasone, 10 µm S3.1 or 
10 µm S3.4. After two days the medium was replaced by DMEM containing 
10% FCS and 1.6 µM insulin. One week later lipid vacuoles were visualized 





GC induced muscle atrophy was investigated using C2C12 myotube model. 
C2C12 cells were allowed to reach 90% confluency at which point the 
medium was replaced by DMEM containing 2% horse serum and 1 µM 
insulin. To stop cells dividing the culture was treated with 4 µg/ml Arac 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). After 1 week cells were 
treated for 24 hours with dexamethasone, S3.1 or S3.4 and fixed in 
glutaraldehyde. Glutaraldehyde causes autofluorescence which allows 
visualization under a fluorescent microscope. 
Western Blot 
Samples for Western blot were made by treating 5 x 106 lymphocytes for 
10 minutes with 10 µM dexamethasone followed by 10 minutes 
stimulation. When using cell lines 20 µg of protein was loaded, as 
determined by BCA (Pierce, Etten-Leur, The Netherlands). Cells were 
pelleted and lysed in lysis buffer (0.1% NP40, 50 mM Tris HCl, 1 mM EDTA, 
1 mM EGTA, 150 mM NaCl, 200 µM Na3VO4, 10 mM NaF) containing 
protease inhibitors (Roche, Mannheim, Germany) for 20 minutes on ice. 
Samples were spinned down, sample buffer was added to the supernatant 
and heated to 95 °C for 5 minutes, cooled on ice and sonicated. Samples 
were blotted overnight at 4°C in buffer containing 20% methanol on PVDF 
membrane (Millipore, Bedford, USA). The membrane was blocked with 5% 
BSA for 1 hour at RT followed by overnight incubation with the primary 
antibody at 4°C. 
Immunoprecipitation 
For immunprecipitation experiments 10 x 107 cells were used per 
condition. Cells were pelleted and lyzed as described above. The 
supernatant was precleared by adding 10 µl Protein A/G UltraLink resin 
(Pierce Biotechnology, Rockford, USA) for 30 minutes at 4°C. Beads were 
spinned down and discarded. Samples were incubated with 2 µg primary 
antibody and 25 µl beads for 2 hours at 4°C. Beads were washed with PBS, 
sample buffer was added and heated to 95°C for 5 minutes. 
Preparing Nuclear Extracts 




Cells were grown in 10cm plates till approximately 80% confluency. After 
completing the treatment, medium was replaced with ice cold PBS and 
cells were scraped while on ice. Cells were spinned down, supernatant 
discarded and the pellet was resuspended in 200 µl of buffer 1 (25 mM 
Hepes, pH 7.9, 5 mM KCl, 0.5 mM MgCl2, 1 mM DTT, protease inhibitors). 
200 µl Buffer 2 (Buffer 1 + 0.1% NP40) was added and tubes were rotated 
for 15 minutes at 4°C. Nuclei were spinned down for 1 minute at 2500 rpm 
at 4°C. Supernatant was transferred to new tube as cytosolic fraction. 
Pellet was washed in 1 ml ice cold PBS followed by resuspension in 400 µl 
of Buffer 3 (25 mM Hepes, pH 7.9, 350 mM Na, 400 mg sucrose, 0.05% 
NP40, 1 mM DTT, protease inhibitors) and 1 hour of rotation at 4°C. Tubes 
were spinned down and the supernatant transferred as the nuclear 
fraction. Equal volumes were loaded on gel. 
Immunofluorescence 
Subcellular localization of the GR was visualized by using a GR-GFP fusion 
construct which was transiently tranfected in HCT116 colorectal cancer 
cells. Actin was stained red using phalloidin-TRITC (Sigma, Zwijndrecht, The 
Netherlands) and the nucleus with DAPI included in the Slowfade mounting 
fluid (Life Technologies, Bleiswijk, The Netherlands). 
Formation of lipid vacuoles during fibroblast-adipocyte differentiation was 
visualized by staining triglycerides and lipids with the lysochrome Oil Red 
O. The C2C12 myotubes were visualized using the autofluorescence caused 
by fixation with 2% glutaraldehyde. 
Competition Assay 
Binding of the compounds to the GR was tested in a whole cell in vitro 
competition assay using [3H]dexamethasone. Per condition 3 x 106 PBL 
were stimulated for 15 minutes with PHA at 37°C. Tubes were then 
incubated for one hour at room temperature with compound and 
[3H]dexamethasone. Samples were spinned down at 400 G and 
supernatant discarded. The cells were washed three times by resuspending 





measured in a scintillation counter using Utima gold scintillation fluid 
(Perkin Elmer, Groningen, The Netherlands).  
 Quantification and Data Analysis 
Measurement of the thickness of myotubes was done in arbitrary units 
using the measuring tool of Photoshop CS6 (Adobe Systems Benelux BV, 
Amsterdam, Nederland). Thickness of each myotube was measured at 
three different places. Quantification of the Oil Red O staining and 
densitometric measurements of Western blot were done using ImageJ (U. 
S. National Institutes of Health, Bethesda, Maryland, USA). For data and 
statistical analysis we used Excel 2010 (Microsoft, Redmond, WA, USA) and 
Graphpad Prism (Graphpad Software Inc, La Jolla, CA, USA). 
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Background: The repertoire of immunomodulators that can be used for the 
treatment of inflammatory bowel disease (IBD) is limited. The use of these 
drugs is further restricted by the occurrence of side effects in a proportion 
of patients. Miltefosine (hexadecylphosphocholine) is a lipid drug 
developed in the eighties for treatment of cancer but is nowadays best 
known for its application in the oral treatment of Leishmaniasis. Although 
the exact mechanism of action of miltefosine has yet to be elucidated the 
drug has previously been shown to inhibit phospholipases and protein 
kinase C, both key components of pro-proliferative signal transduction in T 
cells.  
Methods: Stimulated PBL were treated with miltefosine and proliferation 
was measured. We use the CD45RBhigh T cell transfer colitis model to 
investigate the effect of miltefosine treatment on intestinal inflammation. 
Effects on the severity of colitis were studied by histochemical- and 
immunohistochemical staining and cytokine levels were determined using 
a cytokine bead array. 
Results: Miltefosine inhibited T cell proliferation in vitro. In the transfer 
model miltefosine significantly ameliorated the severity of colitis as 
measured by clinical, (immuno)histochemical and biochemical parameters.  
Conclusions: Miltefosine inhibits T cell proliferation and effectively reduces 
inflammation in the T cell transfer model.  The drug may therefore be a 







A limited number of drugs is available for the treatment of inflammatory 
bowel disease. In Crohn’s disease for example, glucocorticoids can be used 
for remission induction but are generally not advised for long term 
treatment because of their limited value for remission maintenance and 
important side effects. Thiopurines and methotrexate are widely used but 
unfortunately only work in a proportion of patients and are sometimes 
poorly tolerated. If tolerated, the drugs can show important side effects 
such as bone marrow suppression or pancreatitis. Even if patients are 
started on anti-TNF antibodies immunomodulators are often used as co-
treatment to increase the efficacy of the anti-TNF and prevent the 
development of anti-TNF neutralizing antibodies. Therefore there is a clear 
need for the identification of novel candidate immunomodulators for 
remission induction or maintenance in patients with IBD.  
Miltefosine is an ether lipid drug originally designed in the eighties for the 
treatment of cancer. Systemic treatment with the drug has been tested in 
phase I20 and phase II clinical trials in advanced colorectal cancer,13 soft 
tissue sarcoma,19 squamous cell head and neck cancer.18 In oncology 
miltefosine only made it a phase III trial that showed effectiveness as a 
topical palliative treatment for cutaneous metastases of breast cancer.11 In 
the mean time however it was found that miltefosine showed activity 
against Leishmania in animal models10 and clinical trials showed 
spectacular therapeutic efficacy in patients with visceral leishmaniasis.8,15 
Miltefosine is well absorbed, has a half life of 7 days5 and is generally well 
tolerated at a dose of 100-150 mg/day that is used for the treatment of 
Leishmaniasis. The most important side effect of doses up to 150 mg/day 
are mild-to-moderate nausea and vomiting which occur mostly in the first 
two weeks of treatment and are often transient.8,15 Furthermore, mild and 
reversible elevations in the aminotransferases and creatinine have been 
described.8,15  
The mechanism of action of miltefosine is incompletely understood. 
Miltefosine is chemically related to membrane phospholipids and generally 




believed to act by modulating signaling events at cellular membranes.2 It 
has been reported that miltefosine inhibits phospholipase C, phospholipase 
D and protein kinase C (PKC).2 Since activation of T cells critically depends 
on activation of phospholipase C and PKC we hypothesized that treatment 
with miltefosine might inhibit T cell activation. Indeed, it has previously 
been reported that miltefosine inhibits T cell proliferation in mixed 
lymphocyte reactions and showed inhibitory activity in an ovalbumin 
induced mouse model of delayed type hypersensitivity in mice3 and in 
patients with atopic dermatitis.4  
Here we find that miltefosine inhibits both phytohemagglutanin and 
staphylococcal enterotoxin B mediated T cell proliferation. Our 
experiments show that treatment of mice with miltefosine ameliorates 






Material and Methods 
Reagents and Antibodies 
Anti-mouse CD3 (A0452), biotin labeled goat anti-rat and streptavidin-HRP 
complex were purchase from DAKO (Heverlee, Belgium). An poly HRP 
labeled anti–rabbit antibody (DPVR110HRP) was purchased from 
Immunologic (Duiven, The Netherlands). FITC rat anti-mouse Ly-6G 
(553127), FITC Rat anti-Mouse CD45RB (553099) and PE-Cy™5 rat anti-
mouse CD4 (553050) were purchased from BD Pharmingen (Breda, The 
Netherlands). F4/80 Rat anti-Mouse, clone BM8 (T2006) was purchased 
from BMA Biomedicals (Augst, Switzerland). Rabbit F(ab’)2 Anti-Rat IgG 
(6130-01) was purchased from Southern Biotech (Birmingham, Alabama, 
USA). Miltefosine was purchased from Cayman Chemical (Huissen, The 
Netherlands). Sheep anti-rat IgG Dynabeads were purchased from 
Invitrogen (Oslo, Norway) 
Cells 
Human peripheral blood lymphocytes (PBLs) were isolated from whole 
blood of healthy volunteers by Ficoll-Isopaque density gradient 
centrifugation. After washing monocytes were separated from 
lymphocytes by percoll density gradient centrifugation. The lymphocytes 
were cultured in IMDM (Gibco, Verviers, Belgium) supplemented with 10% 
heat inactivated fetal calf serum. For proliferation experiments cells were 
stimulated for 24 hours. Lymphocytes were stimulated with PHA (10µg/ml) 
or SEB (100 ng/ml). Proliferation was measured using a 3H-thymidine 
incorporation assay. Mouse splenocytes were isolated from spleen from 
C57BL/6 mice. Spleens were homogenized and passed through a 70 m 
strainer. 
Mouse experimental colitis CD45RBHigh transfer model 
C.B-17 SCID mice and wild type BALB/c mice were ordered from Harlan 
(Boxmeer, The Netherlands). Transfer of CD45RBHigh CD4+ cells was 
performed as previously described by Read and Powrie.14 In short; for 




every three SCID mice CD45RBHigh cells were isolated from the spleen of a 
single wild type BALB/c mouse. A single cell suspension was created by 
forcing the spleens through a cell strainer. Erythrocytes were removed by 
adding erythrocyte lysis-buffer followed by negative depletion of 
macrophages, B cells and CD8+ cells using magnetic beads. The remaining 
CD4+ cell enriched cell suspension was labelled and CD45RBHigh and 
CD45RBLow cells were isolated on a FACS sorter. Colitis was induced by 
injecting 4 ∙ 105 CD45RBHigh cells intraperitoneally. Control mice received a 
combination of 4 ∙ 105 CD45RBHigh cells and 2 ∙ 105 CD45RBLow cells. The 
inflammation developed over a period of 8 to 10 weeks. Two groups of ten 
SCID mice each were injected with CD4+CD45RBHigh cells and one group of 
ten mice was injected with a combination of CD4+CD45High and 
CD4+CD45RBLow cells. Because the first two groups have a reconstituted T 
cell repertoire lacking regulatory T cells, they will develop colitis. The last 
group does have regulatory T cells (contained in the CD4+CD45RBLow 
compartment), will not develop colitis and acts as a control group. 
Miltefosine was dissolved in 10% DMSO in PBS. Each mouse received 50 
mg/kg miltefosine twice weekly in 200 µl solution by oral gavage or in the 
case of the positive control group 200 µl 10% DMSO in PBS.The mice were 
euthanized by CO2 inhalation followed by removal of the spleen and colon. 
Body weights were recorded three times a week, and wasting disease 
progression was calculated by percentage of weight loss from initial body 
weight. Animals were withdrawn from the study when the weight loss was 
more than 15% compared with the starting weight. Both the colon and the 
spleen were removed and weighed. Two independent investigators blinded 
for treatment allocation scored the colons for stool consistency, visible 
fecal blood, and macroscopic inflammation using a scale of 0–3 per item 
with a maximum score of 9. Tissue weights were recorded and used as an 
index of disease related intestinal wall thickening. Colons were 
subsequently divided longitudinally into two parts: one part was 
immediately frozen in liquid nitrogen for protein extraction and cytokine 
determination, while the second part was stored in formalin and 







H&E sections were blindly scored by an independent experienced GI 
pathologist (SLM). The histology damage score was calculated as the total 
score of points that were scored on 6 criteria. (A) Leukocyte infiltration: 0 =  
normal, 1 = increase in mucosa, 2 = increase in mucosa + submucosa, 3 = 
extending into tunica muscularis. (B) Loss of goblet cells: 0 = none, 1 = < 
10% depletion, 2 = 10-50%, 3 = >50%. (C) Crypt loss: 0 = none, 1 = < 10% 
loss, 2 = 10-50%, 3 = >50%. (D) Epithelial hyperplasia: 0 = normal, 1 = slight, 
2 = 2-3x increased crypt length, 3 = >3x increase. (E) Ulceration: 0 = none, 4 
= present. (F) Crypt abcesses: 0 = none, 4 = present. The histological 
damage score ranged from 0 points to a maximum of 20 points. 
Immunohistochemistry 
For immunohistochemical staining slides were deparaffinized, dehydrated 
and immersed in 1.5% H2O2 in phosphate-buffered saline (PBS) for 30 min. 
Different methods of antigen retrieval were used for the different 
antibodies. For the F4/80 staining slides were cooked for 10 min in 0.1 M 
sodium citrate (pH 6), for the CD3 staining they were cooked for 10 min in 
Tris/EDTA buffer (10 mM Tris, 1 mM EDTA (pH 9)). For the Ly6G staining 
antigen retrieval was performed by incubation of the slide in 0.025% 
pepsin in 0.1 M HCl at 37 °C for 15 min. Subsequently slide were blocked 
with Teng-T (10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin, 0.05% 
[vol/vol] Tween-20, pH 8.0) for 30 min, followed by incubation overnight at 
4 °C with the primary antibody in PBS with 0.1% Triton X-100 and 1% 
bovine serum albumin. For detection of F4/80 an avidin–biotin detection 
system was used. Secondary antibodies were diluted in PBS with 10% 
human serum and incubated for 1 h at room temperature (RT). Slides were 
then incubated for 1 h with horseradish peroxidase-conjugated avidin–
biotin complex. For detection of CD3 and Ly6G the BrightVision detection 
system (Immunologic) was used. Peroxidase activity was detected with 
Sigma Fast 3,3-diaminobenzidine Tablets (Sigma, D4293). Sections were 
counterstained with hematoxylin, dehydrated and mounted with Pertex 




(Histolab 00801). Macrophages, neutrophils and T cells were counted 
blindly in 10 intercrypt spaces per mouse. 
Cytokine Measurements 
Human PBL were seeded in a 96 well plate and treated and stimulated for 
48 hours. IL-2 cytokine levels were determined by ELISA (Biolegend, San 
Diego, USA) following manufacturer’s instructions.   
Cytokine levels in mice were determined in colon mucosa. Colon 
homogenates were obtained using a Heidolph SilentCrusher M 
homogenizer at 4°C in 500 µl lysis buffer (Cell Signaling Technology, 
Beverly, CA) supplemented with protease inhibitors (Roche, Almere, The 
Netherlands). Samples were centrifuged at 24,000g for 10 minutes at 4°C 
and stored at -80°C until cytokine measurement. Protein content was 
determined using the BCA Protein Assay (Thermo Scientific Pierce, Etten-
Leur, the Netherlands), and cytokine levels in homogenates were measured 
using the Cytometric Bead Array System (BD Biosciences, Breda, the 
Netherlands) following the manufacturer’s instructions.  
Statistical Analysis 
Results are shown as means ± standard error of the mean (SEM) unless 
otherwise indicated. For statistical analysis, one way analysis of variance 
(ANOVA) was used followed by a Bonferroni post-test. Results were 







Miltefosine inhibits T cell proliferation 
Previous studies have shown that miltefosine treatment inhibits T cell 
proliferation in a mixed lymphocyte reaction.3 We used two stimuli that 
directly activate the T cell receptor in different ways to confirm this 
observation. The concentration miltefosine used is within physiologically 
relevant range.5 Phytohemagglutinin (PHA) binds CD3 directly17 and 
nonspecifically. This results in the potential activation of all T cells. 
Staphylococcal Enterotoxin B (SEB) is a superantigen that activates a large 
proportion of the T cell population by binding directly to the Vß chain of 
the T cell receptor, activating over 20% of the total T cell repertoire.6 We 
chose SEB in addition to PHA as it has previously been described that SEB 
induces steroid resistance in T cells.7 T cells stimulated with PHA were 
highly sensitive to dexamethasone whereas SEB induced a state of partial 
steroid resistance as described (Fig. 1A). In contrast, T cell proliferation 
induced with PHA and SEB was equally sensitive to miltefosine (Fig. 1B). We 
subsequently isolated mouse splenocytes from C57BL/6 mice and 
stimulated these with both PHA and SEB. The sensitivity of mouse 
splenocytes to both PHA and SEB is less than that of human cells (Fig. 1C) 
but as in the human cells PHA and SEB showed a similar sensitivity to 
miltefosine treatment. And finally we measured IL-2 cytokines levels in the 
medium of PHA or SEB stimulated human PBL treated with different doses 
of miltefosine (Fig. 1D). IL-2 secretion by both PHA and SEB stimulated PBL 
showed sensitivity to miltefosine treatment. Stimulation of human PBL 
with PHA results in very low levels of IL-2 secretion9. 
These results confirm the previous observation that miltefosine inhibits 
proliferation of T cells and suggests that miltefosine may suppress 
proliferation of T cells in conditions that cause steroid resistance. 





FIGURE 1. Miltefosine inhibits T cell proliferation. (A) Human PBL were stimulated 





different doses of dexamethasone. Data shown are absolute and relative 
proliferation as measured by 3H incorporation. PBL treated with SEB show partial 
steroid insensitivity as previously described. (B) Human PBL were stimulated with 
either PHA (10 µg/ml) or SEB (100 ng/ml) for 24 hours in the presence of different 
doses of miltefosine. Data shown are absolute and relative proliferation as 
measured by 3H incorporation. PBL treated with SEB show no insensitivity to 
miltefosine. (C) Mouse splenocytes were stimulated with either PHA (10 µg/ml) or 
SEB (100 ng/ml) for 24 hours in the presence of different doses of miltefosine. 
Data shown are absolute and relative proliferation as measured by 3H 
incorporation. Mouse splenocytes show sensitivity to miltefosine that is similar to 
humans. Each data point represents the mean and SEM of four independent 
samples. (D) Human PBL IL-2 cytokine levels as measured by ELISA. Human PBL 
were stimulated with either PHA (10 µg/ml) or SEB (100 ng/ml) for 48 hours in the 
presence of different doses of miltefosine. Both the production of IL-2 by PHA and 
by SEB stimulated PBL are sensitive to miltefosine. Each data point represents the 
mean and SEM of four independent samples. 
Miltefosine suppresses inflammation in the CD45RBHigh transfer model 
To investigate if miltefosine might be a candidate immunomodulator for 
IBD we used the experimental transfer colitis model. In this model SCID 
mice are reconstituted with CD4+CD45RBHigh cells. This population lacks the 
subset of T cells present in the CD4CD45RBLow population that are required 
to suppress the development of colitis.1 We treated mice with a twice 
weekly dose of 50 mg/kg miltefosine by oral gavage. To allow the 
transferred T cells to home to the intestine and repopulate the mice, we 
started treatment with miltefosine at two weeks after adoptive transfer. 
Oral gavage with vehicle was used as a placebo treatment. In the course of 
two months placebo treated CD45RBhigh transplanted SCID mice developed 
severe inflammation of the gut. Two mice died before the end of the 
experiment. One mouse in the miltefosine treated group died due to a 
complication of the oral gavage. The other mouse was in the group of 
placebo mice and was taken out before the end of the experiment due to 
weight loss > 15%. At completion of the experiment at day 60, mice treated 
with miltefosine had lost significantly less weight than placebo treated 
mice (Fig. 2A) suggesting a reduction in the severity of disease. Indeed, 
inspection of the colon showed that the colon of placebo treated animals 




was severely affected whereas colons of miltefosine treated animals 
showed remarkably less edema and contained normal stool pellets (Fig. 
2B). Treatment with miltefosine significantly reduced the disease activity 
index to levels comparable to controls (Fig. 2C). Colon weight was 
substantially increased in CD45RBhigh reconstituted placebo treated mice 
compared to control mice. Colon weight of miltefosine treated mice was 
substantially reduced compared to placebo treated animals and not 
significantly different from control mice that were reconstituted with both 
CD45RBhigh and CD45RBlow cells (Fig. 2D). A similar observation was made 
for spleen weight which was reduced to levels controls by treatment with 
miltefosine (Fig. 2E).    
 
FIGURE 2. Miltefosine treatment reduces inflammation in CD4CD45RBHigh transfer 
model. (A) Average weight of each group of mice as a percentage of the starting 
weight during the course of the experiment. The control group (black open circle) 





inflammation. Both the placebo treatment group (red inverted triangle) and the 
miltefosine treated (50 mg/kg twice weekly) group (blue closed circle) received 
CD4CD45RBHigh only. (B) Representative examples of colons from mice in the 
indicated groups. The colon in the colitis group is clearly inflamed and void of stool 
while the colon of the treated group shows no signs of inflammation and is filled 
with solid pellets, comparable to the healthy control. (C) Disease score for 
different groups. (D) Colon weight. (E) Spleen weight. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001. Control = CD4CD45RBhigh+low, placebo = CD4CD45RBhigh + placebo, 
miltefosine = CD4CD45RBhigh + miltefosine. 
To confirm the gross morphological examination at the histopathological 
level, coded H&E stained slides where examined by a blinded experienced 
GI pathologist (SLM) and the degree of inflammation was scored. Mice in 
the placebo treated group showed clear infiltrates of leukocytes, loss of 
goblet cells, crypt damage, epithelial hyperplasia, ulcerations and crypt 
abcesses (Fig. 3A-C). In contrast, in the mucosa of mice that were treated 
with miltefosine, all aspects of inflammation were significantly reduced 
compared to placebo treated mice (Fig. 3A-C). None of the 
histopathological hallmarks of colitis in the miltefosine treated animals was 
significantly different from control animals without colitis (Fig. 3A).  




FIGURE 3. Miltefosine treatment improves the histopathological score of colitis. 
(A) Individual components of the histopathological colitis score. (B) Total score. (C) 
Representative images of H&E stained slides of colons from mice in the indicated 
groups. Control = CD4CD45RBhigh+low, placebo = CD4CD45RBhigh + placebo, 
miltefosine = CD4CD45RBhigh + miltefosine. Original magnification in C: 100x. * = P < 
0.05, ** = P < 0.01, *** = P < 0.001. 
We subsequently analyzed the recruitment of individual leukocyte subsets 
to the mucosa (Fig. 4). We used F4/80 as a marker of macrophages, Ly6G 
for neutrophils and CD3 for T cells. The number of infiltrating cells of each 
type was counted per intercrypt space. Per mouse 9 intercrypt spaces were 
counted in 3 high power field images (3 adjacent inter crypt spaces per 
image). In placebo treated animals with colitis, the number of infiltrating 
macrophages, neutrophils and T cells was substantially increased 
compared to controls. Treatment with miltefosine significantly reduced 
influx of all three cell types. Both macrophage and neutrophil infiltration 





FIGURE 4. Reduced influx of different leukocyte subsets in miltefosine treated 
animals. (A) Quantification and representative images of the presence of 
macrophages as determined by immunohistochemistry for F4/80. (B) 
Quantification and representative images of the presence of neutrophils as 
determined by immunohistochemistry for Ly6G. (C) Quantification and 
representative images of the presence of T cells as determined by 




immunohistochemistry for CD3. Control = CD4CD45RBhigh+low, placebo = 
CD4CD45RBhigh + placebo, miltefosine = CD4CD45RBhigh + miltefosine. Original 
magnifications 100x. * = P < 0.05, *** = P < 0.001. 
To investigate the immunomodulatory effect of miltefosine treatment on 
cytokine production, cytokine levels were determined in whole colon 
lysates (Fig. 5). In the colitis group the inflammation caused a significant 
increase in the levels of the pro-inflammatory cytokines IL-6, TNFα, INFγ 
and IL-17. The levels of the Th2 related cytokine IL-4 and of the anti-
inflammatory cytokine IL-10 remained unchanged. In mice treated with 
miltefosine the increase of pro-inflammatory cytokines IL-6, TNFα, INFγ 










FIGURE 5. Miltefosine treatment reduces the production of pro-inflammatory 
cytokines. Measurement of mucosal levels of different cytokines in colonic 
homogenates by cytokine bead array. Control = CD4CD45RBhigh+low, placebo = 
CD4CD45RBhigh + placebo, miltefosine = CD4CD45RBhigh + miltefosine. ns = not 
significant, * = P < 0.05. 
Discussion 
Miltefosine was initially developed as an anti-cancer drug but has largely 
failed clinical development for oncology. After preclinical experiments in 
mice10 it was found that miltefosine has a surprising efficacy for the 
treatment of Leishmaniasis.8,15 Since it was previously found that 
miltefosine may suppress T cell activation,3,4 we investigated miltefosine as 
a potential immunomodulator in a mouse model of colitis. We found that 
miltefosine efficiently inhibited PHA mediated T cell proliferation at 
physiologically attainable concentrations.5 In addition, miltefosine fully 
inhibited SEB induced T cell proliferation which is known to be only 
partially sensitive to dexamethasone. To test the feasibility of miltefosine 
treatment as a way to suppress intestinal inflammation we used the 
experimental CD4CD45RBHigh transfer colitis mouse model. We chose this 
model as it is characterized by an expression profile of proinflammatory 
molecules that is relatively similar to human IBD, especially compared to 
the chemical colitis models.16 Treatment with miltefosine was started two 
weeks after the T cell transfer as in previous studies using this model the 
mice started losing weight after two weeks.12 The mice were dosed 50 
mg/kg twice per week as miltefosine has a long half life. Treatment with 
miltefosine resulted in a remarkable reduction of all aspects of the severity 
of colitis that we examined. Most of the hall marks of colitis that we 
measured in this model were no longer significantly different between 
CD45RBhigh transplanted colitic mice treated with miltefosine and control 
mice that received both CD45RBhigh and CD45RBlow cells. 
As miltefosine is already marketed for use in Leishmaniasis under the brand 
name Impavido (by Zentaris) it could be an attractive immunomodulator to 
examine for use in humans with IBD. Miltefosine has an excellent oral 





trials in humans have shown an acceptable safety profile with reversible 
abnormalities in liver biochemistry and renal function.8,15 The major side 
effects of miltefosine are nausea and vomiting which could be problematic 
in patients with IBD. However these side effects are often transient.8,15 The 
safety and side effects of long term miltefosine use that would be required 
for maintenance therapy in patients with IBD have not been established.      
In conclusion, we find that miltefosine inhibits T cell proliferation at 
physiologically relevant concentrations in vitro. Miltefosine strongly 
reduced severity of colitis in the murine transfer model of colitis. Our data 
suggest that miltefosine is an interesting candidate anti-inflammatory drug 
for patients with IBD.  
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Miltefosine is an ether lipid initially developed for cancer treatment in the 
early eighties. Miltefosine largely failed development for oncology 
although it has been approved for the topical treatment of breast cancer 
metastasis. It was subsequently discovered that miltefosine is a highly 
effective treatment for visceral Leishmaniasis, a parasitic disease which 
affects millions worldwide and causes an estimated 30.000 fatalities each 
year. Oral treatment with miltefosine is in general well tolerated and has 
relatively few adverse effects. The exact mechanism of action of 
miltefosine treatment is still a matter of investigation. Its close 
resemblance to phospholipids allows it to be quickly taken up by cell 
membranes and affect related processes such as lipid metabolism and 
signaling through lipid rafts. These processes play an important role in the 
immune response and it comes as no surprise that miltefosine has been 
successfully tested for the treatment of a number of immune mediated 
diseases in preclinical models of disease. Drug repurposing of miltefosine 
for immune mediated diseases may provide an opportunity to expand the 






Miltefosine or hexadecylphosphocholine (HePC) was developed in the early 
eighties as a potential cytostatic drug. The drug largely failed development 
for oncology and is now best known as an oral treatment for Visceral 
Leishmaniasis, a lethal disease that is the result from infection with the 
parasite Leishmania. Discovery of its potential as an anti-parasitic drug has 
in recent years renewed scientific interest in the drug and it’s mechanism 
of action. Development of new drugs is a costly and time-consuming 
process with a high risk of failure at multiple steps along the road of 
preclinical and clinical development. This makes repurposing of existing 
drugs with established side effects for novel indications an attractive 
alternative to classical drug development. Miltefosine has been extensively 
investigated in large clinical trials and appears to be relatively safe with 
limited and reversible side effects. In this review we will focus on the 
potential to repurpose miltefosine as an anti-inflammatory drug for 
immune mediated diseases. Of note, we will not cover perifosine, an alkyl-
phospholipid developed to improve oral tolerability. Assuming that the 
mechanism of action of perifosine is similar to that of miltefosine, 
perifosine could be an alternative candidate for repurposing. However, the 
number of studies that address perifosine for other applications than the 
treatment of cancer is very limited.  
Miltefosine (hexadecylphosphocholine) is an alkyl-phospholipid or ether-
lipid with structural resemblance to lysophosphatidylcholine (LPC), a type 
of phospholipid that is present in the cell membrane and makes up around 
3% of the cellular membrane. LPCs have a very short half-life as they are 
quickly metabolized by phospholipases and acyltransferases. In the LPC 
analogues miltefosine, perfosine and edelfosine an acyl group is replaced 




by an alkyl group (Fig. 1) which makes the compounds metabolically stable 
(Eibl and Unger 1990).  
 
Fig. 1. Chemical structure of lysophosphatidylcholine and synthetic analogues. 
Lysophosphatidylcholine (also known as lysolecithin) is a natural occurring 
phospholipid present in cellular membranes. The lipid is easily metabolized, a 
problem that was solved in synthetic analogues by replacing the acyl group with a 
more resistant alkyl group. This change causes the ester, linking oxygen to the acyl 
group, to be changed into an ether.  
The first stable LPC analogue was synthesized with an interest in enhancing 
macrophage mediated anti-tumor immunity (Munder PG, Fischer H, 
Weltzien HV, Oettgen HF, Westphal O (1976) Lysolecithin analogs: a new 





Res 17:174) as it was found that LPCs increased the phagocytic capacity of 
peritoneal macrophages (Burdzy, Munder et al. 1964). It was subsequently 
discovered that some of these alkyl-phospholipids possessed direct 
cytostatic properties, shifting the interest away from the 
immunomodulatory properties. As the ability to inhibit cell growth 
appeared to be related to structural properties it was attempted to create 
the most minimal structure required. This resulted in a new group of 
molecules, the alkylphosphocholines and the discovery of miltefosine and 
edelfosine (Munder, Modolell et al. 1979).  
Screening of miltefosine in cancer cell lines suggested that miltefosine 
possessed potent anti-neoplastic properties. Miltefosine inhibited cell 
growth in various leukemic cell lines (Unger, Damenz et al. 1989) and 
reduced tumor weight and size in dimethylbenzanthracene induced 
mammary carcinomas and transplanted mammary tumors in rats in vivo 
(Scherf, Schuler et al. 1987). However, miltefosine appeared only effective 
against some cell types, as no effect was observed in a variety of other 
cancer cell lines such as rat DS-carcinosarcoma, AH 13s sarcoma and L5222 
leukemia, and mouse L1210 and P388 lymphocytic leukemia cells, Lewis 
lung carcinoma cells and B16 melanoma cells. The reason for this 
differential sensitivity of cancer cell lines to miltefosine has not been 
established,  
Development of miltefosine for oncology 
Intravenous administration of miltefosine is hemolytic and thus clinical 
applications have been limited to topical and oral treatments. A phase II 
dose-finding study in cancer patients confirmed previous phase I data that 




the major dose limiting toxicity were nausea and vomiting and suggested a 
maximum dose of 150 mg daily split into three doses (Verweij, Planting et 
al. 1992). Oral treatment was subsequently tested in a number of 
oncological trials, including a phase II study for treatment of soft tissue 
sarcomas (Verweij, Krzemieniecki et al. 1993), a phase II study in advanced 
non-small cell lung cancer (Berdel, Becher et al. 1992), a phase II study in 
advanced colorectal cancer (Planting, Stoter et al. 1993), a phase II study in 
advanced breast cancer (Unger, Becher et al. 1993) and a phase II study for 
squamous cell head and neck cancer (Verweij, Gandia et al. 1993). None of 
these phase II clinical trials showed a sign that miltefosine treatment might 
affect disease progression. The only trials that showed an effect of 
miltefosine are studies in which miltefosine was applied topically. A 6% 
topical miltefosine solution was successfully applied in a phase II study for 
cutaneous T cell lymphomas (Dumontet, Thomas et al. 2006) and a 
multicenter randomized placebo-controlled phase III study for the 
treatment of skin metastasis of mammary carcinoma (Leonard, Hardy et al. 
2001). Reasonable efficacy was observed in the latter trial with 2 out of 24 
patients achieving a complete response of the skin lesions (0/27 for 
placebo) and 6 out of 24 showing partial response (1/27 for placebo).  
Leishmaniasis 
Leishmaniasis is a disease caused by infection of macrophages by a 
protozoan parasite belonging to the genus Leishmania. The parasites are 
transferred by a type of sandflies that only lives in (sub)tropical regions, 
restricting the disease to those areas. Although the infection can lead to 





Visceral leishmaniasis is characterized by bouts of fever, weight loss, 
hepatosplenomegaly and anemia. It is a lethal disease if left untreated 
(Chappuis, Sundar et al. 2007). Unfortunately the yearly incidence of 
visceral leishmaniasis is estimated at 200.000 to 400.000 per year 
worldwide, with around 20.000 to 30.000 fatalities a year (Alvar, Velez et 
al. 2012). In 95% of the cases the disease can be quite effectively treated 
with intravenous injections of amphotericin B or pentavalent antimonial 
drugs (sodium stibogluconate and meglumine antimoniate). These drugs 
are inexpensive but treatment requires a trained physician to perform the 
injection and patients often succumb before reaching a doctor. More 
importantly, the number of patients showing resistance to treatment is 
increasing and patients with VL in combination with AIDS are generally 
refractory to treatment with pentavalent antimonial drugs. 
The development of an in vitro model for infecting primary mouse 
peritoneal macrophages with Leishmania donovani in the 1980-ies allowed 
screening of large libraries of compounds for possible new treatments 
(Croft 1986). These screenings resulted in the discovery of alkyl 
phospholipids as possible candidates (Croft, Neal et al. 1987). In 1992 it 
was first shown that Leishmaniasis can indeed be treated with miltefosine 
in vivo. Mice infected with Leishmania donovani and Leishmania infantum 
were treated orally with miltefosine and compared to standard treatment 
using sodium stibogluconate. Parasitic levels in spleen and liver after four 
weeks of treatment showed that miltefosine is more potent in both 
suppressing and killing Leishmania parasites than sodium stibogluconate in 
mice (Kuhlencord, Maniera et al. 1992).  




The use of miltefosine as an oral treatment for visceral leishmaniasis has 
been tested in numerous trials (Sundar, Rosenkaimer et al. 1998; Jha, 
Sundar et al. 1999; Sundar, Jha et al. 2002; Sundar, Sinha et al. 2011). 
Different treatment strategies have been used but in general patients with 
visceral leishmaniasis receive 50 or 100 mg of miltefosine daily for a 
duration of 28 days. On average treatment was well tolerated and adverse 
effects were limited to gastro-intestinal side effects such as vomiting and 
diarrhea. Treatment with miltefosine resulted in a 90 to 100 percent cure 
rate.  
Immunomodulatory effects of miltefosine 
The development of alkyl phospholipids initially started with the aim to 
create an immunomodulator that would increase anti-tumor phagocytic 
capacity of tumor associated macrophages. Similar to the original 
compounds that development started out with, miltefosine exhibits 
immunomodulatory properties.  
Stimulatory effects on the innate immune response 
There are a number of reports that suggest that miltefosine may stimulate 
multiple aspects of monocyte and macrophage mediated immunity. Such 
effects may explain the potent clearance of Leishmania parasites that have 
their niche inside macrophages.. For example, Balb/c mouse monocytes 
and macrophages treated with miltefosine showed a more potent response 
to LPS, with enhanced secretion of TNFα and release of NO (Eue, Zeisig et 
al. 1995; Zeisig, Rudolf et al. 1995; Ghosh, Roy et al. 2013). In a similar 





increase in NO release but miltefosine did increase their phagocytic 
capacity. Not only did sensitized macrophages phagocytize more S. 
cerevisiae after miltefosine treatment but miltefosine also increased the 
number of macrophages that participated in the process (Ponte, Alves et 
al. 2012).  
One report investigated the effect of miltefosine on circulating monocytes 
and cytokine levels in patients suffering from cutaneous Leishmaniasis 
(Mukhopadhyay, Das et al. 2011). In 12 patients that completed 4 months 
of miltefosine treatment (100 mg/day) the percentage of CD14+ 
monocytes decreased while CD16+ monocytes increased. This shift 
indicated that miltefosine treatment may have triggered maturation of the 
monocyte population towards a more pro-inflammatory phenotype. Levels 
of monocyte associated pro-inflammatory cytokines such as TNF-a, IL-6, IL-
1b and IL-8 were significantly increased compared to these levels at the 
moment of presentation of the disease. Of course it cannot be excluded in 
this study that some of these effect were indirect and a systemic response 
to the eradication of the Leishmania parasites.  
In a case study of one patient suffering from cutaneous Leishmaniasis 
treated with miltefosine, tissue biopsies were taken from the lesional area. 
Quantitative analysis of mRNA expression showed a significant decrease of 
TNFα, IL-10 and TGFβ levels while IFNγ and CD40 were significantly 
increased when comparing before to after treatment (Ansari, Ramesh et al. 
2008). CD40 is a costimulatory molecule found on antigen presenting cells 
that helps to stimulate T helper cells which in turn produce IFNγ stimulating 
macrophages. Again, this was a single patient and it is difficult to judge if 




the changes in expression are the direct result of the miltefosine treatment 
or alternatively result from the eradication of parasite-laden macrophages. 
The initial development of alkyl phospholipids as compounds that stimulate 
macrophage phagocytosis, the potent parasite clearance by Leismania 
infected macrophages together with some of the experiments above 
suggest that treatment with miltefosine potentiates monocyte and 
macrophage mediated innate immunity.  
Inhibitory effects on the adaptive immune response 
The reason for a potential role for miltefosine and other alkyl 
phospholipids in immune mediated diseases is that miltefosine potently 
inhibits T cell activation (Baumer, Wlaz et al. 2010; Verhaar, Wildenberg et 
al. 2013). This effect has been verified in animal models where 
inflammation was successfully reduced using miltefosine. We investigated 
the effect of miltefosine in a CD4CD45RBhigh transfer mouse model of 
inflammatory bowel disease (IBD). In this model, SCID mice, which lack T 
and B cells, are transplanted with CD45RBhigh T cells resulting in chronic 
inflammation of the gut that develops over the course of several weeks. 
Miltefosine, given twice weekly, greatly reduced colonic inflammation in 
this model. Miltefosine improved clinical parameters such as weight loss, 
significantly improved the pathology score and reduced the expression of 
pro-inflammatory cytokines il-6, tnf-α and ifnγ to levels no longer 
significantly different from control mice without colitis (Verhaar, 
Wildenberg et al. 2013). These findings may make miltefosine an attractive 
candidate for the treatment of IBD. Although the cause of IBD remains 





the innate immune system predisposes to an excessive response of the 
adaptive immune response to intestinal microbiota (Marks, Harbord et al. 
2006; Hayee, Rahman et al. 2010; Uhlig 2013). Given the results discussed 
above miltefosine may have a dual therapeutic effect in IBD by both 
stimulating macrophage mediated innate immunity and reducing excessive 
activation of T cell mediated adaptive immunity.  
Baumer et al. investigated the effect of miltefosine treatment in a number 
of animal models addressing its effect on Th1 or Th2 related inflammatory 
responses and feasibility for use in atopic dermatitis. The models use ear 
thickness as a measure of inflammation. In an ovalbumin induced delayed 
type hypersensitivity model (DTH) miltefosine was able to significantly 
reduce ear swelling. Likewise in the more Th2 orientated mouse model of 
toluene diisocyanate induced hypersensitivity treatment with miltefosine 
significantly reduced the ear swelling and pro-inflammatory cytokine 
expression, both when administered systemically as well as topically 
(Baumer, Wlaz et al. 2010).  
Topical application of a 6% miltefosine solution was compared with 1% 
hydrocortisone in a small clinical trial of 16 patients (Dolle, Hoser et al. 
2010). Patients with at least two different target lesions were treated 
topically with one drug on each lesion for three weeks. Both treatments 
effectively reduced the severity of the disease and reduced the number of 
infiltrating lymphocytes in the lesions. Follow-up of the patients revealed a 
more sustained effect of miltefosine treatment. Interestingly, closer 
examination revealed a local increase in the number of FoxP3+ regulatory T 
cells in the miltefosine treated lesions while the number of FoxP3+ cells 




was reduced by hydrocortisone. An important potential advantage of 
miltefosine over hydrocortisone was that in contrast with hydrocortisone, 
miltefosine did not affect proliferation of cells in the basal layer of the 
epidermis. Indeed, again in contrast with hydrocortisone, no reduction in 
epidermal thickness was observed with miltefosine. 
Miltefosine and allergic disease 
A potential role for miltefosine in allergic disease was suggested when it 
was shown that miltefosine can reduce histamine release from rat primary 
mast cells (Grosman 1990). Mast cells contain large granules with 
inflammatory mediators such as cytokines, proteases, histamine, serotonin 
and eicosanoids. Mast cells release their granules in response to activation 
by pattern recognition receptors or cross-linking of the IgE receptor. 
Degranulation causes redness of the skin, swelling and itching. 
Miltefosine has also been shown to inhibit histamine release in human 
mast cells  (Weller, Artuc et al. 2009; Batista, Friedrichson et al. 2010; 
Batista, Schlechtingen et al. 2011). Ten minutes of pretreatment with 25 
µM miltefosine reduced anti-IgE induced histamine release by more than 
50%. These findings were translated into a small study in which the effect 
of miltefosine was tested on the allergic response to a standard skin prick 
test. Five allergic patients were treated on both arms with either placebo 
or a 6% miltefosine solution. The inflammatory response was measured by 
the diameter of the resulting wheal and erythema. Miltefosine was able to 
significantly reduce the inflammatory response that resulted from injection 
with an allergen. A control condition in which the patients were injected 





Miltefosine has also been tested in a number of other mast cell related 
conditions. One such condition, mastocytosis, involves the accumulation of 
mast cells in various organs, most commonly in the skin. This rare condition 
affects mostly children and skin manifestations causes symptoms related to 
mast cell mediator release such as pruritus and flushing. 39 Adult patients 
were tested in a double-blind, placebo-controlled trial with a topical 6% 
miltefosine solution and the glucocorticoid clobetasol (0.5 mg/ml) for 2 
weeks. Although it seems that miltefosine may have reduced weal 
formation in this study none of the differences reached statistical 
significance and it seems the study was under powered to detect a 
meaningful difference (Hartmann, Siebenhaar et al. 2010).  
Chronic urticaria, is a kind of idiopathic rash that is relatively common 
affecting up to 1% of the population in the US. In most cases the underlying 
cause is unclear but the rash is the result of activated mast cells. Urticaria 
can be treated with anti-histamines but with chronic urticaria most 
patients respond poorly and are often resistant. In a multicenter 
randomized, double-blind, placebo-controlled study that included 54 anti-
histamine resistant chronic urticaria patients, miltefosine was tested as an 
oral drug (Magerl, Rother et al. 2012). Patients took increasing dosages 
miltefosine (up to 150 mg/daily unless intolerable adverse effects) daily for 
4 weeks. At the end of the treatment period, miltefosine treated patients 
showed substantial improvement as was clear from a specific urticaria 
activity score and a decrease in the number of wheals. Miltefosine 
treatment did not reduce the intensity of pruritus. 




Collectively these data suggest that miltefosine could be a potential drug 
for mast cell related conditions.  
Side effects 
Miltefosine has few side effects but those found may hamper long term 
use. From the phase II trials for the oral use of miltefosine with cancer 
patients it has become clear that daily dosages of 150 mg and higher cause 
potentially severe gastrointestinal side effects resulting in loss of appetite, 
nausea and vomiting (Verweij, Planting et al. 1992). This can be solved by 
combining with anti-emetics but in some cases the side effects are dose 
limiting. Development of a better tolerated formulation for oncological 
indications was suspended due to the discovery of perifosine, a better 
tolerated oral anticancer drug (Crul, Rosing et al. 2002).  
Miltefosine treatment may have teratogenic effects. Studies on embryonic 
development and organogenesis of rats suggested an embryotoxic, 
fetotoxic and teratogenic risk (Sindermann and Engel 2006). The same was 
reported from studies in rabbits, although with the exception of the 
teratogenic effect. Due to these findings and because of a lack of human 
study results, use of miltefosine during pregnancy is contraindicated. This is 
especially a problem due to its long half-life. Six months after treatment 
miltefosine can still be measured in serum and it is therefore advisable to 
use contraception for half a year after stopping treatment. 
In some patients the renal function is affected and a rise in creatinine levels 
is observed. In most cases this effect is reversible. Studies in dogs showed 





2009). Miltefosine might have a direct effect on renal function but change 
in fluid balance due to gastrointestinal effects might contribute. Supporting 
this hypothesis, Leishmaniasis patients treated with miltefosine sometimes 
show elevated creatinine serum levels during episodes of vomiting and 
dehydration (Sindermann and Engel 2006).  
To summarize, a treatment schedule of 50-100 mg miltefosine daily is in 
general well tolerated and rarely leads to serious or treatment limiting 
adverse effects. Studies on the miltefosine treatment of VL clearly indicate 
that such a treatment schedule can be maintained for at least 4 weeks. 
These data indicate that the potential of miltefosine as a maintenance 
treatment for IBD could be investigated.   
Mechanism of action 
The precise mechanism of action of miltefosine is lacking and may be 
different for different cell types. Because miltefosine was originally 
selected as a cytostatic drug, most of the research is focused on explaining 
how miltefosine induces apoptosis in cancer cells. And even though the 
effect of miltefosine on macrophages, lymphocytes and mast cells appears 
to be different, may involve similar pathways.  
Miltefosine shows resemblance to the membrane phospholipid 
lysophosphatidylcholine. It’s structural properties allow miltefosine to 
integrate into the cellular membrane (Rakotomanga, Loiseau et al. 2004). 
From there it redistributes to endoplasmic reticulum, Golgi-, nuclear- and 
mitochondrial membranes. How this happens is unclear but in Caco-2 
colorectal cancer cells the process appears to be partly ATP dependent 




suggesting active transport. The normal membrane recycling process may 
be responsible for the remainder of the intracellular transport of the drug 
(Menez, Buyse et al. 2007). Because alkyl-phopholipids, such as 
miltefosine, are more resistant to metabolizing enzymes, they accumulate 
in the membranes possibly affecting the continuous turnover of 
endogenous phospholipids.  
One of the most important effects of miltefosine incorporation into the cell 
membrane is believed to be inhibition of phosphatidylcholine (PC) 
synthesis. PC is the most abundant phospholipid in cellular membranes of 
eukaryotic cells and interference with its production may predispose the 
cell to undergo apoptosis (Wieder, Orfanos et al. 1998; van der Luit, Budde 
et al. 2002). Miltefosine affects PC synthesis by inhibiting 
CTP:phosphocholine cytidylyltransferase, the rate limiting enzyme in the PC 
biosynthesis pathway at the endoplasmatic reticulum. This is supported by 
the fact that apoptosis can be prevented by supplementing miltefosine 
treated cells with exogenous lysoPC, an alternative precursor for the 
synthesis of PC. As apoptosis induced by other triggers could not be 
rescued by adding lysoPC, this is a strong suggestion that indeed inhibition 
of PC synthesis is the mechanism of miltefosine induced apoptosis (Boggs, 
Rock et al. 1995; Baburina and Jackowski 1998; Van Der Luit, Budde et al. 
2003).  
In addition to inhibition of PC synthesis, miltefosine also impairs signaling 
molecules through inhibition of phospholipases. Phospholipases hydrolyze 
phospholipids and inhibition results in a decrease in breakdown products, 





phosphatidic acid (PA). Further downstream, alkyl-phospholipids may 
impact proliferation and cell survival through effects on the kinase Akt 
(Song, Ouyang et al. 2005). Under normal conditions, once recruited and 
positioned at the plasma membrane, Akt can be activated. Although this 
has not been described for miltefosine, studies on perifosine suggest that 
treatment affects the recruitment of Akt to the plasma membrane and 
displacements of its ligands PIP3 (phosphatidylinositol (3,4,5)-
trisphosphate, PtdIns(3,4,5)P3) or PIP2 (phosphatidylinositol (3,4)-
bisphosphate, PtdIns(3,4)P2).  
All of these effects could be cause by disturbance of membrane integrity 
and the functionality of lipid rafts (Kondapaka, Singh et al. 2003). 
Miltefosine increases the membrane fluidity in macrophages (Ghosh, Roy 
et al. 2013) an effect that has been reported to decreases antigen 
presentation and stimulation of T cells (Chakraborty, Banerjee et al. 2005). 
On the other hand miltefosine has an affinity for sterols and is known to 
stabilize sterol rich areas such as lipid rafts which increase antigen 
presentation (Jimenez-Lopez, Rios-Marco et al. 2010). And indeed 
macrophages treated with miltefosine show an enhance ability to stimulate 
T cells resulting in a higher production of IL-2, IL-12, TNFα and NO 
production (Ghosh, Roy et al. 2013). The effect of miltefosine on 
membrane integrity could also very well explain why mast cells are 
inhibited in their IgE dependent histamine release. Upon activation, IgE 
receptors cluster in organized microdomains (Weller, Artuc et al. 2009; 
Silveira, Mazucato et al. 2011). Likewise T cell activation is dependent on 
the formation and organization of T cell receptor microclusters and 
formation of the immunological synapse (Kabouridis and Jury 2008). 




Signaling molecules that have been implicated as targets for miltefosine 
treatment in cancer, such as Akt, Ras/Raf-1, PLC and second messengers 
like PA and DAG, are also important mediators in cells of the immune 
system. Inhibition of even one of these molecules could explain for 
example the inhibition of lymphocyte proliferation. Of course future 
investigations will have to shed more light on this. 
Conclusion 
Miltefosine is an alkyl-phospholipid that was initially tried unsuccessfully in 
several phase II trials in oncology and hematology. Originally this class of 
compounds was identified for its stimulatory effect on macrophage 
phagocytosis and several groups have observed that miltefosine may 
stimulate myeloid cell mediated immunity. At the same time miltefosine 
shows profound inhibition of T cell activation and miltefosine was 
successfully applied in preclinical models of atopic dermatitis and 
inflammatory bowel disease. Given the well-established and relatively 
limited side effects and oral route of administration miltefosine may be a 
candidate for drug repurposing for immune mediated diseases that are in 
dire need for novel therapeutic options such as inflammatory bowel 
disease.  
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Summary and general discussion




This thesis is composed of two parts. In the first part the focus lies on 
glucocorticoids. Glucocorticoids have been used worldwide for more than 
half a century. This would suggest that it is a safe drug to use but this is not 
the case. Soon after it was introduced in the clinic it became apparent that 
its use is accompanied by adverse effects. Sixty years later the drug is still 
first line treatment for many inflammatory conditions. In this thesis a new 
mechanism of glucocorticoid action is described which includes effects on T 
cell activation that does not include the regulation of genes. We found that 
this mechanism is important to the overall effect of glucocorticoid 
treatment and used it to develop a screening assay with the intention of 
finding a glucocorticoid ligand that induces exclusively non-transcriptional 
effects, possibly providing a safe alternative to conventional 
glucocorticoids. Because only a limited number of these non-
transcriptional effects of GC treatment have been described, it is certainly 
possible that some of the adverse effects are also the result of non-
transcriptional effects. The two compounds S3.1 and S3.4 described in 
chapter 7 are certainly not intended as a final product. These compounds 
were used to develop a pharmacophore, a chemical model describing what 
properties a molecule needs to exhibit to behave similarly. From this model 
more compounds were successfully developed. Work on these compounds 
is in progress.  
The second part of this thesis describes the use of an existing cytostatic 
drug for immunosuppression. Interestingly this drug was developed for the 
treatment of cancer but came from a screening for anti-inflammatory 
drugs. As a cytostatic drug it wasn’t very successful but it got a lot of 
attention when it was found that it could be used to cure visceral 
leishmaniasis. Further research on the mechanism of action resulted in 
studies that showed a potential for immune suppression. We too describe 
successful use of miltefosine for the treatment of chronic inflammation of 
the colon using a transfer mouse model. Miltefosine knows very few 
adverse effects and is a cheap drug that can be taken orally. However, it 
can cause nausea resulting in reduced appetite and emesis. Although we 
feel that the transfer model compares best to actual inflammatory 
conditions, it remains to be a mouse model and may not reflect IBD in 






The first chapter is a simple introduction to glucocorticoids (GCs) in 
general. Mentioned are the advantages and disadvantages of 
glucocorticoid treatment, outlining the general problem of developing save 
GCs. 
Chapter 2 
Glucocorticoid analogues have been around for more than half a century. 
Just like so many other drugs, GCs were not developed with the intention 
to suppress inflammation. Isolation, characterization and further 
development  were fueled by  war time rumors. Afraid the enemy would 
gain an advantage over them, allied forces initiated large scale research 
which eventually led to post-war development of GCs. As the rumors 
turned out to be false, a real purpose for the drug was lacking. Justification 
for the major investment led to the idea of dividing the few milligram GC 
available amongst lead scientists. Eventually it was Philip S. Hench who first 
tested the drug on rheumatoid arthritis patients and discovered its anti-
inflammatory effect. 
Chapter 3 
The major downside of glucocorticoids as a drug is the induction of a great 
number of adverse effects. If not for these, the drug would be almost ideal. 
Most adverse effects have few consequences for the long term and can in 
general be ignored. But with higher concentrations and longer periods of 
treatment, the severity and the number of complications increase. If 
development of a GC analogue lacking adverse effects turns out to be 
impossible, it may be of great importance to understand how GCs cause 
these adverse effects on a very basic level. This may eventually provide a 
way to suppress adverse effects by concomitant treatment targeting the 
underlying cause.  
In the last decades biomedical science has benefitted greatly from the 
development of new methods in the various fields such as genetics and 
proteomics. With it our understanding of GC signaling and how adverse 
effects are caused, has increased. This chapter is a broad overview of our 
current understanding of the underlying molecular mechanism responsible 
for GC side effects. The different side effects are addressed separately, 
focusing on the common major adverse effects associated with GC 
treatment. These include obesity, thinning of the skin and appearance of 
striae, muscle atrophy, osteoporosis, diabetes, hypertension, cataract and 




glaucoma and finally effects on the central nervous system. In general, 
tissues in which GCs are part of the normal homeostasis are effected most 
by addition of exogenous GCs. 
Chapter 4 
From the first moment they entered the clinic, GCs have been remodeled 
to improve their properties, resulting in a whole range of GC analogues. 
Initially steps aimed for more potent anti-inflammatory properties by 
increasing half-life, followed by decrease of off-target effects by  selecting 
for a higher affinity for the GR and lower affinity for other nuclear hormone 
receptors such as the mineralocorticoid receptor. Although this approach 
did provide GC analogues with more potent anti-inflammatory properties 
and a reduction in off-target effects originating from activation of other 
nuclear hormone receptors, it also increased adverse effects that arise 
from GR related transcriptional regulation of genes that are not involved in 
inflammation. In the last decades we have started to unravel how GCs 
work. And while we learn our notion of what to take into account while 
developing new GCs changes. Not so long ago it was believed that GCs 
repress pro-inflammatory genes while activating genes responsible for 
adverse effects and that this could be exploited to develop safe GCs. This 
chapter is a brief overview of what is currently known about GC action and 
what should be considered when developing GCs with more favorable 
properties. 
Chapter 5 
Classically GCs act through the regulation of genes. This mechanism 
requires a certain amount of time before actual changes can be noticed. 
However, it’s not uncommon for GC effects to appear after a much briefer 
stretch of time. Patients suffering from osteoarthritis can be treated 
palliatively by injecting GCs directly into the affected joint. The pain relief 
that follows is almost instantaneously. This is just one example of GC 
effects that are too fast to involve regulation of genes. And because these 
effects do not include transcriptional regulation, they are termed non-
transcriptional or non-genomic GC effects. 
This chapter addresses the rapid effects of GC treatment on T helper cells 
and more specifically on a complex of proteins that is associated with the T 
cell receptor (TCR). In a previous study[1] the kinome profile of T helper 





(PepChip). The results indicated that two kinases, LCK and FYN, are 
inhibited by a short GC treatment of 10 minutes. These kinases, LCK in 
particular, are the first messengers to transfer a signal from the activated 
TCR. LCK is vital to T cell activation. T cells lacking this kinase cannot be 
activated through the TCR[2].  
This chapter describes how, after stimulation of T cells, a complex is 
formed at the TCR. In this complex LCK associates with CD4, and FYN 
associates CD3. Both are associated with the chaperone protein Hsp90 and 
the GR. When stimulated T cells are treated with GC, all of these 
associations are lost. From this a model is proposed in which the GR forms 
an essential part of the TCR related complex. When the GR binds ligand, it 
breaks it bonds with the other proteins an leaves the complex, thereby 
destabilizing it causing all associations to be lost and the complex to break 
up. As a result TCR signaling is abrogated. 
Chapter 6 
Another aspect of GCs, besides the adverse effects, less desirable in a drug, 
is loss of sensitivity or even total loss of response. This group of patients 
can be subdivided into separate groups based on the underlying 
mechanism responsible for said loss. Mechanisms include increased 
clearance of GCs, increased pro-inflammatory transcription factors, altered 
posttranslational modifications to the GR, defective histone acetylation and 
finally overexpression of the dominant negative beta form of the GR. At 
least in vitro it is possible to induce steroid insensitivity in T cells by 
activation with super antigens. This chapter describes how the 
superantigen staphylococcal enterotoxin B (SEB) activates T lymphocytes 
through stimulation of a signaling cascade that deviates from the normal 
TCR-LCK mediated transduction pathway. This pathway leads to activation 
of T cells without the need for LCK activation. It includes a guanine 
nucleotide-binding protein Gαq and the phospholipase PLCβ2 and 
converges with the canonical TCR signaling cascade at the level of PKC. 
Stimulation with SEB triggers T cell proliferation that is less sensitive to GC 
treatment than with a normal mitogen. Direct activation of PKC with the 
phorbol ester PMA in combination with the ionophore ionomycin induces 
proliferation that is completely resistant to GC treatment. Taken together 
this suggests that the inhibitory effect of GC treatment on T cell 
proliferation is primarily a non-genomic effect on LCK and associated 
proteins. This places the relevance of non-genomic GC effects for the 




overall anti-inflammatory effect of GC treatment in a whole new 
perspective.  
Chapter 7 
Inhibition of T cell proliferation is one of the primary features of the anti-
inflammatory effect of GC treatment. The findings in the previous chapter 
suggest that this is based on a non-transcriptional effect. This chapter 
describes how through a combination of in silico and in vitro screening two 
GR ligands were discovered that do not induce transcriptional effects but 
do cause dissociation of the TCR associated molecules leading to inhibition 
of T cell proliferation.  
For the screening, potential GR ligands were selected from a public 
database of commercially available compounds. Selection was based on 
similarity to the basic cortisol structure or gonane. This resulted in a 
quarter of a million potential candidates which in a second round of 
screening were fitted to a virtual GR binding pocket in four different known 
conformations. A selection was made of the compounds that fitted best 
and 80 of these were purchased. Each compound was then tested for its 
capacity to inhibit T cell proliferation. Using a cell line stably transfected 
with a glucocorticoid responsive element (GRE) reporter construct, 
compounds that induced transcriptional activation were excluded. 
Applying this strategy two compounds, S3.1 and S3.4, were identified that 
repress T cell proliferation with a potential comparable to prednisolone. 
Further examination of these compounds revealed an inhibition of TCR 
related signaling similar to the non-genomic effect of dexamethasone. But 
unlike dexamethasone these compounds did not induce adipogenesis or 
muscle atrophy, as was assessed through in vitro assays. 
Chapter 8 
In search for a PLCβ inhibitor (Chapter 5) we came across a drug called 
miltefosine. Indeed as had been previously reported[3], miltefosine inhibits 
PLCβ but not very specifically. We did however notice a very strong 
inhibitory effect on T cell proliferation and wondered if miltefosine could 
be used as an anti-inflammatory drug. In inflammatory bowel diseases 
(IBD) T lymphocytes play an important role in the underlying cause[4]. 
Using a mouse CD4+ transfer model we tested miltefosine as a means to 
suppress chronic inflammation. The SCID mice in this model lack T and B 





of chronic inflammation of the colon. The level of inflammation was 
assessed by colon weight and length, stool consistency, spleen weight, 
pathology score, influx of macrophages, neutrophils and T cells and the 
presence of cytokines. Oral treatment with miltefosine reduced 
inflammation significantly.  
Chapter 9 
Miltefosine (or hexadecylphosphocholine) was originally intended for the 
treatment of cancer but failed in most of the clinical trials due to lack of 
significant improvement of the patient’s condition. In the end it was only 
effective as a topical treatment for skin metastasis of patients with breast 
cancer. But just as the drug was threatened to be forgotten completely, it 
was discovered that miltefosine was an excellent treatment for patients 
suffering from visceral Leishmaniasis. This parasitic disease is relatively 
unknown to people in the western part of the world because it only affects 
the economically less developed areas near the equator. This is because 
Leishmaniasis is transmitted through a type of sandfly that is only 
indigenous to those particular areas. Nevertheless, Leishmaniasis is, next to 
malaria, the second biggest parasitic killer worldwide with an estimated 
25.000 fatalities each year. Although an effective treatment existed, it 
required a trained physician to administer the drug. Miltefosine can be 
taken orally, has few adverse effects and is relatively cheap.  
This chapter mainly focusses on what has been published on miltefosine in 
relation to suppression of the immune systems and cells belonging to the 
immune system. These publications can be broadly divided into three 
separate groups. Effects on macrophages, effects on T cells and effects on 
mast cells. This data is used to build a case in favor of testing miltefosine as 
an immunosuppressive drug. And finally the underlying molecular 
mechanism is discussed based on what is currently known about how 
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Nederlandse samenvatting van dit proefschrift 
Hoofdstuk 1 
Het eerste hoofdstuk is een eenvoudige introductie op glucocorticoïden 
(GC) in het algemeen. Hierin worden de voor- en nadelen van behandeling 
met GC kort opgesomd, een beeld schetsend van de problemen die men 
kan verwachten bij het ontwikkelen van nieuwe veilige GC.     
Hoofdstuk 2 
GC afgeleiden zijn al meer dan 50 jaar in omloop. Net als met zoveel 
medicijnen, zijn GCs niet ontwikkeld met als doel ontsteking te remmen. De 
isolatie,  karakterisatie en verdere ontwikkeling van GCs werden gedurende 
de WOII aangewakkerd door een gerucht. Om te voorkomen dat de 
tegenstander een voordeel kreeg werd door de geallieerden op grote 
schaal onderzoek verricht, hetgeen er uiteindelijk toe leidde dat vlak na de 
oorlog een eerste batch GCs geïsoleerd werd. Toen bleek dat de geruchten 
nergens op gebaseerd waren, hadden de GCs ineens geen nut meer. Om de 
enorme investering te rechtvaardigen werd de paar milligram die er op dat 
moment was, verdeeld onder de beste wetenschappers om zo alsnog een 
doel te vinden. Uiteindelijk was het Phillip S. Hench die als eerste GCs 
testte op patiënten met reumatoïde artritis en zo de ontstekingsremmende 
werking ontdekte. 
Hoofdstuk 3 
Het enorme nadeel van GCs als medicijn is het bestaan van de vele 
bijwerkingen. Was het niet voor deze bijwerkingen dan zou het medicijn 
bijna ideaal te noemen zijn. De meeste bijwerkingen hebben geen gevolgen  
voor de lange termijn en kunnen in het algemeen worden genegeerd. Maar 
bij gebruik in hoge concentraties of voor langere perioden neemt de ernst 
en het aantal bijwerkingen toe. Als uiteindelijk blijkt dat ontwikkeling van 
een veilige GC zonder bijwerkingen niet mogelijk is, zal basale kennis over 
het ontstaan van deze bijwerkingen essentieel zijn. Deze kennis kan 
vervolgens gebruikt worden om manieren te bedenken om de bijwerkingen 
zelf te bestrijden. 
In de afgelopen jaren heeft biomedische wetenschap veel voordeel 
behaald uit de ontwikkeling van vele nieuwe onderzoeksmethoden in de 





op het gebied van GC werking en bijwerking enorm toegenomen. Dit 
hoofdstuk is een overzicht van wat bekend is over de onderliggende 
moleculaire mechanismen van de verschillende bijwerkingen. De 
verschillende bijwerkingen worden apart besproken waarbij wordt 
gefocust op de belangrijkste meer algemene bijwerkingen. Daaronder 
vallen overgewicht, verdunnen van de huid en het ontstaan van striae, 
spier atrofie, osteoporose, diabetes, hypertensie, staar en glaucoma, en als 
laatste effecten op het centrale zenuw stelsel. Over het geheel genomen 
kan worden geconstateerd dat de bijwerkingen het grootst zijn in weefsels 
waar GCs een rol spelen in de normale homeostase. 
Hoofdstuk 4 
Vanaf het eerste moment dat GC de kliniek betraden is er aan de 
moleculen gesleuteld om ze te verbeteren, hetgeen erin heeft geresulteerd 
dat er tegenwoordig een hele selectie aan GC analogen op de markt is. 
Aanvankelijk richtte men zich vooral op het vergroten van de 
ontstekingsremmende werking door de halfwaardetijd te verlengen, 
gevolgd door een reductie in bijwerkingen middels vergroting van de 
specificiteit voor de GR en een reductie in binding aan andere nucleaire 
hormoonreceptoren zoals de mineralocorticoïde receptor. Alhoewel deze 
aanpak inderdaad meer potente GCs opleverde en een reductie in de 
bijwerkingen die gerelateerd zijn aan binding en activatie van andere 
nucleaire hormoonreceptoren, resulteerde het tevens in een toename van 
GR specifieke bijwerkingen. De laatste jaren zijn we beter gaan begrijpen 
hoe GCs werken. En met de toename van kennis veranderen ook de zaken 
waar we rekening mee houden bij de ontwikkeling van nieuwe GCs. Nog 
maar enkele jaren geleden waren veel wetenschappers van mening dat GCs 
pro-inflammatoire genen remden terwijl alle bijwerkingen het gevolg 
waren van activatie van genen en dat dit uitgebuit kon worden om zo een 
veilig GC te ontwikkelen. Dit hoofdstuk bespreekt kort wat we op dit 
moment weten over hoe GCs werken en waarmee rekening gehouden 
moet worden bij ontwikkeling van GCs met betere eigenschappen. 
Hoofdstuk 5 
Het klassieke beeld van hoe GCs werken is dat ze genen reguleren. Dit 
mechanisme vereist een zekere hoeveelheid tijd voordat het effect 
waargenomen kan worden. Maar het is niet ongewoon voor GC effecten 





kunnen worden behandeld via een injectie met GCs in het ontstoken 
gewricht. De pijnverlichting die volgt is vaak onmiddellijk. Dit is slechts één 
voorbeeld van GC effecten die te snel plaats vinden om te kunnen worden 
toegeschreven aan genregulatie. Omdat deze effecten ontstaan zonder dat 
daar transcriptionele regulatie bij betrokken is, worden zij niet-
transcriptionele- of niet-genomische effecten genoemd. 
Dit hoofdstuk beschrijft de snelle effecten van GC behandeling op T 
lymfocyten en dan specifiek die effecten die betrekking hebben op een 
complex van eiwitten dat geassocieerd is met de T cel receptor (TCR). In 
een vorige studie[1] werd het kinoom van geactiveerde en met GCs 
behandeld T lymfocyten bestudeerd. Daaruit bleek dat twee kinases LCK en 
FYN geremd werden in hun activatie door een korte behandeling met GCs. 
Deze kinases, LCK met name, zijn de eerste boodschappers die het signaal 
van de TCR door geven. Daardoor is LCK doorslag gevend voor T cel 
activatie. T cellen die geen LCK tot expressie kunnen brengen, kunnen niet 
worden geactiveerd via de TCR[2]. 
Dit hoofdstuk beschrijft hoe, na stimulatie van T cellen, een complex wordt 
gevormd bij de TCR. In dit complex is LCK geassocieerd met CD4 en FYN 
met CD3. Beide zijn geassocieerd met het chaperonne eiwit Hsp90 en de 
GR. Wanneer gestimuleerde T cellen worden behandeld met GCs, worden 
al deze interacties verbroken. Uitgaande van deze bevindingen wordt een 
model voorgesteld waarin de GR een essentieel onderdeel vormt van het 
TCR gerelateerde complex. Wanneer de GR ligand bindt, verbreekt deze 
zijn verbindingen met de andere eiwitten in het complex en verlaat deze 
om naar de kern te kunnen. Hierdoor raakt het hele complex 
gedestabiliseerd, verliezen alle eiwitten hun onderlinge verbindingen en 
valt het complex uiteen. Het uiteindelijke resultaat is blokkade van TCR 
signalering. 
Hoofdstuk 6 
Een ander aspect van GCs dat, naast de bijwerkingen, nadelig is voor het 
medicijn, is verlies van gevoeligheid van de patiënt voor de behandeling. 
Deze patiënten groep kan worden onderverdeeld in aparte groepen met 
verschillende  onderliggende mechanismen verantwoordelijk voor dit 
verlies. De oorzaak kan zijn een verhoogde klaring van GCs, verhoogde 
expressie van pro-inflammatoire transcriptie factoren, gewijzigde post-





laatste overexpressie van de dominant negatieve beta vorm van de GR. In 
vitro is het mogelijk om steroïde ongevoeligheid te induceren door T 
lymfocyten te stimuleren met super-antigenen. Dit hoofdstuk beschrijft 
hoe het super-antigen staphylococcal enterotoxin B (SEB) T cellen 
stimuleert via een signaal transductie pad dat afwijkt van de normale TCR-
LCK gemedieerde activatie. Deze route bevat guanine nucleotide-bindend 
proteïne Gαq en de fosfolipase PLCβ2 en voegt zich weer bij de TCR-LCK 
gemedieerde route op het niveau van proteïne kinase C (PKC). Stimulatie 
van T cellen met SEB resulteert in een celdeling die minder gevoelig is voor 
behandeling met GC dan wanneer deze cellen met een normaal antigeen 
gestimuleerd zouden zijn. Directe activatie van PKC met de forbol ester 
PMA in combinatie met de ionofoor ionomycine resulteert in celdeling die 
geheel resistent is tegen G behandeling. Te samen suggereren deze 
resultaten dat het remmende effect van GC op T lymfocyt deling berust op 
een niet-transcriptioneel effect van GC behandeling. Dit plaatst de 
relevantie van de niet-transcriptionele effecten van GC behandeling, voor 
het gehele anti-inflammatoire effect, in een heel nieuw daglicht. 
Hoofdstuk 7 
Remming van T lymfocyt deling door GC behandeling is een van de 
belangrijkste onderdelen van het totale ontstekingsremmende effect van 
GCs. De bevindingen zoals beschreven in het vorige hoofdstuk suggereren 
dat dit berust op een niet-genomisch effect. Dit hoofdstuk beschrijft hoe, 
door een combinatie van in silico en in vitro screening, twee GR liganden 
werden gevonden die geen transcriptionele effecten induceren maar wel 
dissociatie van TCR geassocieerde moleculen leidend tot remming van T 
lymfocyt deling.  
Voor de screening werden potentiele liganden geselecteerd uit een 
publieke database van commercieel verkrijgbare stoffen. Selectie van de 
stoffen werd gebaseerd op basis van overeenkomsten met de basale 
structuur van cortisol ook wel gonane genoemd. Dit resulteerde in een 
kwart miljoen potentiele kandidaten die in een tweede ronde van selectie 
werden gepast in een virtuele GR bindingsholte, gebaseerd op vier 
bekende GR conformaties. De stoffen die het best pasten werden 
geselecteerd en daarvan werden er 80 gekocht. Elke stof werd vervolgens 
getest voor de capaciteit om T lymfocyt deling te remmen. Gebruik makend 
van een cellijn die stabiel getransfecteerd is met een glucocorticoïd 





transcriptionele regulatie induceerde geëxcludeerd. Met deze strategie 
werden er twee GR liganden gevonden, S3.1 en S3.4, die in staat waren T 
lymfocyt deling te remmen met een potentie gelijk aan prednisolon maar 
zonder de transcriptionele activatie. Verdere studie toonde aan dat dit 
effect gelijk was aan het effect zoals eerder beschreven bij dexamethason. 
Maar anders dan dexamethason, induceerde deze stoffen geen vervetting 
of spier atrofie zoals getest met in vitro assays.  
Hoofdstuk 8 
Op zoek naar een remmer van PLCβ (hoofdstuk 5) kwamen we het medicijn 
miltefosine tegen. Zoals eerder gerapporteerd[3] remde miltefosine PLCβ 
maar niet heel specifiek. Het viel ons echter wel op dat miltefosine een 
sterk remmend effect op T lymfocyt deling had en vroegen ons af of 
miltefosine als een ontstekingsremmer gebruikt kon worden. Bij chronische 
ontstekingsziekten van het maag-darm kanaal spelen T lymfocyten een 
belangrijke rol[4]. Door middel van een zogenaamd CD4 transfer muizen 
model werd miltefosine getest als middel om chronische ontsteking te 
remmen. De SCID muizen in dit model hebben geen T en B cellen en 
wanneer deze worden vervangen door een repertoire van alleen T effector 
cellen leidt dit naar verloop van tijd tot een chronische ontsteking van de 
dikke darm. Het niveau van ontsteking werd bepaald door gewicht en 
lengte van de dikke darm, toestand van de uitwerpselen, gewicht van de 
milt, pathologische score, influx in de dikke darm van macrofagen, 
neutrofielen en T cellen en als laatste de toename van lokale cytokines. 
Orale behandeling met miltefosine wist de ontsteking significant te 
remmen.  
Hoofdstuk 9 
Miltefosine (of hexadecylfosfocholine) werd oorspronkelijk ontwikkeld als 
behandeling voor kanker maar faalde in de meeste klinische trials door het 
uitblijven van significante verbetering van de conditie van de patiënten. 
Uiteindelijk bleek miltefosine alleen geschikt als topicale behandeling voor 
huid metastasen van patiënten met borstkanker. Maar net toen miltefosine 
in de vergetelheid dreigde te raken werd ontdekt dat deze stof een 
uitstekende behandeling is voor patiënten met viscerale Leishmaniasis. 
Deze parasitaire ziekte is relatief onbekend in de westerse wereld omdat 
de ziekte alleen financieel minder ontwikkelde gebieden treft rond de 





zandvlieg die alleen in die gebieden voor komt. Niettemin is Leishmaniasis, 
op malaria na, de belangrijkste dodelijke parasitaire aandoening 
wereldwijd met een geschat aantal van 25.000 dodelijke slachtoffers elk 
jaar. Een effectieve behandeling bestond reeds maar vereiste een arts om 
het middel toe te dienen. Miltefosine kan oraal worden ingenomen en is 
relatief goedkoop om te maken. 
Dit hoofdstuk zoemt met name in op wat bekend is over miltefosine als 
remmer van het immuun systeem en de cellen die daartoe behoren. Over 
het geheel genomen kunnen die publicaties in drie groepen worden 
verdeeld. Effect op macrofagen, effect op mast cellen en effect op T cellen. 
Deze data wordt vervolgens gebruikt om het verder testen van miltefosine 
als ontstekingsremmer te onderbouwen. Als laatste wordt het 
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